

Distinct roles for Dectin-1 and Dectin-2 in skin wound healing and neutrophilic inflammatory responses.

著者	Kenji Yamaguchi, Emi Kanno, Hiromasa Tanno, Ayako Sasaki, Yuki Kitai, Takayuki Miura, Naoyuki Takagi, Miki Shoji, Jun Kasamatsu, Ko Sato, Yuka Sato, Momoko Niiyama, Yuka Goto, Keiko Ishii, Yoshimichi Imai, Shinobu Saijo, Yoichiro Iwakura, Masahiro Tachi, Kazuyoshi Kawakami
journal or publication title	Journal of investigative dermatology
volume	141
number	1
page range	164-176
year	2020-06-05
URL	http://hdl.handle.net/10097/00131987

doi: 10.1016/j.jid.2020.04.030

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

**Distinct roles for Dectin-1 and Dectin-2 in skin wound healing
and neutrophilic inflammatory responses**

Kenji Yamaguchi¹ (ORCID: 0000-0003-3313-3048), Emi Kanno^{2*} (ORCID: 0000-0003-2339-122X),
Hiromasa Tanno² (ORCID: 0000-0002-6031-6432), Ayako Sasaki¹ (ORCID: 0000-0002-9261-2359),
Yuki Kitai³ (ORCID: 0000-0003-3271-6807), Takayuki Miura¹ (ORCID: 0000-0002-0437-0880),
Naoyuki Takagi¹ (ORCID: 0000-0001-6415-0233), Miki Shoji¹ (ORCID: 0000-0002-2061-5024),
Jun Kasamatsu⁴ (ORCID: 0000-0001-9718-8377), Ko Sato⁴ (ORCID: 0000-0002-5548-6285),
Yuka Sato² (ORCID: 0000-0003-4234-9617), Momoko Niiyama² (ORCID: 0000-0003-0788-2838),
Yuka Goto² (ORCID: 0000-0002-0874-4819), Keiko Ishii³ (ORCID: 0000-0003-0794-746X),
Yoshimichi Imai¹ (ORCID: 0000-0001-5360-958X), Shinobu Saijo⁵ (ORCID: 0000-0002-3802-8821),
Yoichiro Iwakura⁶ (ORCID: 0000-0002-9934-5775), Masahiro Tachi¹ (ORCID: 0000-0003-2993-3202),
Kazuyoshi Kawakami^{3, 4} (ORCID: 0000-0001-6599-1915)

¹Department of Plastic and Reconstructive Surgery, Tohoku University Graduate School of
Medicine, 2-1 Seiryō-cho, Aoba-ku, Sendai, Japan

²Department of Science of Nursing Practice, Tohoku University Graduate School of
Medicine, 2-1 Seiryō-cho, Aoba-ku, Sendai, Japan

³Department of Medical Microbiology, Mycology and Immunology, Tohoku University
Graduate School of Medicine, 2-1 Seiryō-cho, Aoba-ku, Sendai, Japan

1 ⁴Department of Intelligent Network for Infection Control, Tohoku University Graduate

2 School of Medicine, 2-1 Seiryō-cho, Aoba-ku, Sendai, Japan

3 ⁵Department of Molecular Immunology, Medical Mycology Research Center, Chiba

4 University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan

5 ⁶Division of Laboratory Animals, Research Institute for Biomedical Sciences, Tokyo

6 University of Science, 2669 Yamazaki, Noda, Chiba, Japan

7

8 ***Number of figures: 6***

9 ***Number of supplemental figures: 8***

10

11 ***Corresponding author:*** Emi Kanno, RN, PhD

12 Department of Science of Nursing Practice, Tohoku University Graduate School of Medicine

13 2-1 Seiryō-cho, Aoba-ku, Sendai, Miyagi 980-8575, Japan

14 Phone: +81-22-717-8675; Fax: +81-22-717-7910

15 Email: ekanno@med.tohoku.ac.jp

16

17

18

19

20

21

22

1 **Short Title: Dectin-1 and Dectin-2 in wound healing**

2

3 **Abbreviations used:** *WT*, wild type; *PCNA*, proliferating cell nuclear antigen; α -*SMA*, α -
4 smooth muscle actin; *CLR*, C-type lectin receptor; *DAMPs*, damage-associated molecular
5 patterns; *PAMPs*, pathogen-associated molecular patterns; *PBS*, phosphate buffered saline;
6 *TGF*, transforming growth factor; *VEGF*, vascular endothelial growth factor; *EGF*,
7 epidermal growth factor; *Dectin*, dendritic-cell-associated C-type lectin; *NETs*, neutrophil
8 extracellular traps; *TNF*, tumor necrosis factor; *TLR*, toll-like receptor; *MIP*, macrophage
9 inflammatory protein; *KC*, keratinocyte-derived chemokine; *MMP*, matrix metalloproteinase

10

11 **Key words:** Dectin-1, Dectin-2, wound healing, neutrophils, NETosis

1 **Abstract**

2 C-type lectin receptors (CLRs) recognize microbial polysaccharides. The CLRs Dectin-1 and
3 Dectin-2, which are triggered by β -glucan and α -mannan, respectively, contribute to up-
4 regulation of the inflammatory response. Recently, we demonstrated that activation of the
5 Dectin-2 signal delayed wound healing; in previous studies, triggering the Dectin-1 signal
6 promoted this response. However, the precise roles of these CLRs in skin wound healing
7 remain unclear. This study was conducted to determine the roles of Dectin-1 and Dectin-2 in
8 skin wound healing, with a particular focus on the kinetics of neutrophilic inflammatory
9 response. Full-thickness wounds were created on the backs of C57BL/6 mice, and the effects
10 of Dectin-1 or Dectin-2 deficiency and those of β -glucan or α -mannan administration were
11 examined. We also analyzed wound closure, histological findings, and neutrophilic
12 inflammatory response including neutrophil extracellular trap (NET) formation at the wound
13 sites. We found that Dectin-1 contributed to the acceleration of wound healing by inducing
14 early-phase neutrophil accumulation, whereas Dectin-2 was involved in prolonged
15 neutrophilic responses and NET formation, leading to delayed wound healing. Dectin-2
16 deficiency also improved collagen deposition and TGF- β 1 expression. These results suggest
17 that Dectin-1 and Dectin-2 have different roles in wound healing through their different
18 effects on the neutrophilic response.

19 (*Word count: 199*)

20

21

22

1 INTRODUCTION

2 Skin wounds normally heal through an efficient process that is characterized by inflammation,
3 proliferation, and remodeling. Many cell types, including neutrophils, macrophages, and
4 fibroblasts, are involved in orchestrating the healing process. The inflammatory response
5 causes these cells to secrete several cytokines and growth factors that work together to induce
6 cell migration and remodeling (Pasparakis et al., 2014). Pathogen-associated molecular
7 patterns (PAMPs) and damage-associated molecular patterns (DAMPs) trigger these
8 responses upon being recognized by pattern recognition receptors (PRRs) such as C-type
9 lectin receptors (CLRs) (Girardin et al., 2002, Yan et al., 2017).

10 CLRs are well known for playing key roles in the host defense against fungal pathogens,
11 mostly by recognizing pathogens' cell wall polysaccharides such as β -glucan and α -mannan
12 (Saijo and Iwakura, 2011). Dectin-1 and Dectin-2 contribute to inflammatory responses via
13 activation of NF-kappa B and are triggered by β -glucan and α -mannan, respectively.
14 Additionally, Dectin-1 binds to the endogenous intermediate filament protein vimentin
15 (Thiagarajan et al., 2013), while Dectin-2 interacts with the endogenous protein β -
16 glucuronidase (Mori et al., 2017). Although it is not well understood how CLRs contribute to
17 wound healing, we recently demonstrated that CARD9, an essential signaling adaptor
18 molecule that is triggered by CLRs, was involved in these responses (Kanno et al., 2017). We
19 also found that Dectin-2-mediated signaling led to delayed wound healing through prolonged
20 neutrophilic inflammatory response and accompanying NET formation (Miura et al., 2019).
21 Additionally, administration of β -glucan was reported to improve wound healing (Palma et

1 al., 2006), although it remains unclear how Dectin-1 deficiency affects the neutrophilic
2 responses at wound sites.

3 Neutrophils, the first responder cells in skin injury, are recruited through the influence of
4 chemokines and cytokines such as keratinocyte-derived chemokine (KC) and tumor necrosis
5 factor (TNF)- α . However, only limited information is available about the role of neutrophils
6 in wound healing (Pasparakis et al., 2014). Infiltrating neutrophils play central roles in
7 debridement and anti-microbial defense through phagocytosis and NET formation, a process
8 called NETosis (Kolaczkowska and Kubes, 2013). However, prolonged neutrophil activation
9 is known to cause intractable wounds (Kolaczkowska and Kubes, 2013, de Oliveira et al.,
10 2016). Previously, Wong and co-workers revealed that neutrophils isolated from diabetic
11 humans and mice were susceptible to NETosis when stimulated with the Ca²⁺ ionophore
12 ionomycin, and that the NETs resulted in impaired wound healing (Wong et al., 2015).
13 Additionally, it was reported that bacterial endotoxin lipopolysaccharide (LPS) and α -mannan
14 promoted NETs (Brinkmann et al., 2004; Miura et al., 2019) and that TNF- α primed
15 neutrophils, making them more susceptible to NETosis (Thomas et al., 2012). These earlier
16 observations suggested that NETosis may play an unknown physiological role in the process.
17 It is consistent with this possibility that TNF- α is quickly produced in the early phase of wound
18 healing even under uninfected conditions (Kanno et al., 2011).

19 Based on this background, in the present study, we conducted comparative analyses to
20 define the roles of Dectin-1 and Dectin-2 in wound healing, with particular emphasis on the
21 kinetics of neutrophilic inflammatory responses and NET formation, using mice that were
22 deficient in these CLR. Here, we found that Dectin-1 contributed to the acceleration of

1 wound healing through inducing early phase neutrophil accumulation, whereas Dectin-2 was
2 involved in the prolonged neutrophilic inflammatory response and NETs, which may play a
3 particular role in the regulation of excessive healing response.

4

1 RESULTS

2 **Different kinetics for Dectin-1 and Dectin-2 expression in skin after wounding**

3 To identify the contributions of Dectin-1 and Dectin-2, the expression of these molecules'
4 mRNA was examined. Dectin-1 was rapidly expressed, appearing at 3 hours, peaking at 6
5 hours, and quickly declining thereafter to the baseline level. Dectin-2, however, appeared at 6
6 hours, peaked at 12 or 24 hours, and remained somewhat elevated for up to 7 days (Figure
7 1a). In immunohistochemical analysis, both Dectin-1 and Dectin-2 were detected in
8 infiltrating leukocytes and fibroblasts in the early phase after wounding, but they were not
9 detected in unwounded skin; additionally, the reported endogenous ligands for Dectin-1
10 (vimentin) (Thiagarajan et al., 2013) and Dectin-2 (β -glucuronidase) (Mori et al., 2017) were
11 also detected around the cells expressing these receptors (Figure 1b). As shown in Figure 1c,
12 both Dectin-1 and Dectin-2 were apparently expressed in neutrophils, macrophages, and
13 fibroblasts at 24 hours and also on day 5, although the expression was lower in these cells
14 (Supplementary Figure S1). We also confirmed that the supernatants, which were collected
15 from wounds that contained molecules that activated signaling that was mediated via Dectin-1
16 or Dectin-2 using NFAT-GFP reporter assays (Supplementary Figure S2), and we confirmed
17 that GFP is expressed in Dectin-2-expressing reporter cells but not in Dectin-1-expressing
18 reporter cells.

19

20 **Distinct effects of Dectin-1 and Dectin-2 deficiency on wound healing**

21 To elucidate the distinct roles of Dectin-1 and Dectin-2, we examined the effects of Dectin-1
22 and Dectin-2 deficiency using Dectin-1 knockout (KO) and Dectin-2KO mice. As shown in

1 Figure 2a and b, wound closure was significantly impaired in Dectin-1KO mice but it was
2 enhanced in Dectin-2KO mice compared with WT mice. In Dectin-1KO mice, the re-
3 epithelialization rate was significantly decreased compared with WT and Dectin-2KO mice;
4 in Dectin-2KO mice, however, the re-epithelialization rate was significantly increased (Figure
5 2c). As alternate indicators of wound healing, we evaluated proliferating cell nuclear antigen
6 (PCNA), CD31, and α -smooth muscle actin (α -SMA), which indicate epithelial cell
7 differentiation, vascularization, and myofibroblast differentiation, respectively. As shown in
8 Figure 2d, the counts of PCNA-positive epidermal cells were significantly decreased in
9 Dectin-1KO mice compared with WT and Dectin-2KO mice. CD31-positive vessel counts
10 were markedly decreased in Dectin-1KO mice and enhanced in Dectin-2KO mice compared
11 with WT mice (Figure 2e). Dectin-2 deficiency led to an increase in α -SMA-positive cell
12 numbers (Figure 2f).

13 Because neutrophils play a critical role in inflammatory responses (Wilgus et al., 2013),
14 we examined the effects of Dectin-1 and Dectin-2 deficiency on neutrophil accumulation. As
15 shown in Figure 2g, the neutrophil counts were significantly lower in Dectin-1KO mice
16 compared with WT mice at 6 hours, whereas the opposite results were obtained in Dectin-
17 2KO mice. On day 5, the neutrophil counts remained markedly decreased in Dectin-2KO
18 mice.

19

20 **Distinct effects of Dectin-1- and Dectin-2-mediated activation on wound healing**

21 We next evaluated how Dectin-1- and Dectin-2-activation affected wound healing. We
22 examined the effects of administration of either dZymosan (containing β -glucans, a known

1 Dectin-1 ligand) or α -mannan (a known Dectin-2 ligand). As shown in Figure 3a and b, WT
2 mice treated with dZymosan showed significant acceleration of wound closure, whereas
3 treatment with α -mannan led to a significant delay in wound closure compared with mice
4 treated with vehicle control. These responses were canceled in CARD9KO mice
5 (Supplementary Figure S3). Similar results were obtained using Furfurman (another Dectin-2
6 ligand) instead of α -mannan (Supplementary Figure S4). In dZymosan-treated mice, the re-
7 epithelialization rate was significantly increased compared with vehicle-treated mice, whereas
8 treatment with α -mannan led to delayed re-epithelialization (Figure 3c). Additionally, the
9 hydroxyproline content was significantly decreased in α -mannan-treated mice compared with
10 vehicle- or dZymosan-treated mice (Figure 3d). As shown in Figure 3e–g, the PCNA, CD31,
11 and α -SMA-positive cell counts were significantly increased in dZymosan-treated mice,
12 whereas the opposite results were obtained in α -mannan-treated mice.

13

14 **Effect of topical dZymosan or α -mannan administration on neutrophilic inflammatory** 15 **responses and NETosis**

16 To elucidate the effects of dZymosan and α -mannan on neutrophilic responses, we examined
17 the kinetics of neutrophil accumulation. The proportions of neutrophils, defined as
18 CD45⁺CD11b⁺Ly6G⁺ cells, were evaluated by flow cytometry. In mice treated with
19 dZymosan, neutrophil counts were increased in the early phases compared with other groups,
20 but the counts had returned to baseline levels on day 3. In mice treated with α -mannan,
21 however, neutrophil counts were equivalent to those in the other groups for the first 24 hours,
22 then markedly increased starting on day 3 and peaking on day 5. In vehicle-treated mice,

1 neutrophil counts returned to baseline levels by day 3 (Figure 4a). We confirmed these
2 findings through immunohistochemical analysis (Supplementary Figure S5). The increase in
3 neutrophil counts caused by dZymosan at 6 hours and by α -mannan on day 5 were inhibited
4 in Dectin-1KO mice and Dectin-2KO mice, respectively (Supplementary Figure S6).
5 Additionally, KC and MIP-2 synthesis rates were significantly higher at 6 hours in the
6 dZymosan-treated group compared with the other groups, but were higher on day 3 in the α -
7 mannan-treated group compared with the other groups. TNF- α and interleukin (IL)-17A levels
8 were not different among these groups at 6 hours, but were significantly higher in the α -
9 mannan-treated group on day 3 (Figure 4b). Similar results were obtained regarding leukocyte
10 and macrophage accumulation (Supplementary Figure S7). To clarify the effect of Dectin-1
11 activation, NETs were evaluated in mice treated with dZymosan. As shown in Figure 4c, in
12 contrast to α -mannan treatment, dZymosan treatment did not increase co-localized Cit H3 and
13 Ly6G expression compared with vehicle. Western blotting analysis similarly revealed that
14 dZymosan treatment did not increase Cit H3 expression, whereas α -mannan treatment led to a
15 striking increase on day 5 (Figure 4d and e), but not at 6 hours (Figure 4f).

16

17 **Effects of Dectin-1 and Dectin-2 deficiency, DNase, and neutrophil depletion on NETosis**

18 To address this possibility, we examined NETs under natural conditions without any
19 treatments. As shown in Figure 5a, Cit H3 expression began to increase at 6 hours, reached its
20 peak on day 3, and then began to decrease, although its levels remained higher compared with
21 those in unwounded skin tissues through day 10. Thus, we examined the effects of Dectin-1
22 and Dectin-2 deficiency on NETs. In Dectin-2KO mice, Cit H3 expression was significantly

1 lower compared with WT mice (Figure 5b), whereas there was no significant difference
2 between Dectin-1KO and WT mice (Figure 5c). A previous study reported that DNase 1
3 administration promoted wound healing (Wong et al., 2015), although its effect on NETosis
4 remains to be clarified. As shown in Figure 5d, DNase 1 administration significantly reduced
5 the delay in wound closure in WT mice that were treated with α -mannan, while no such effect
6 was seen in wounds that were not treated with either ligand. On day 3, however, untreated
7 wound closure was significantly accelerated by DNase 1 administration (Figure 5e).

8 We then examined the effect of DNase 1 treatment on NETosis in wound tissues that
9 were treated or not treated with α -mannan. As shown in Figure 5f, this treatment had no
10 significant effect on Cit H3 expression, although Cit H3 expression tended to be higher in
11 untreated wounds. Next, we used anti-Gr-1 mAb to examine the effect of neutrophil depletion
12 on wound closure and NETs in WT mice. As shown in our recent study (Miura et al., 2019),
13 neutrophils were completely depleted by this treatment. Thus, wound closure was
14 significantly accelerated in mice treated with anti-Gr-1 mAb compared with control IgG-
15 treatment (Figure 5g), which supports our hypothesis. Additionally, anti-Gr-1 mAb
16 administration resulted in a significant reduction in Cit H3 expression compared with control
17 (Figure 5h).

18

19 **Effect of Dectin-2 deficiency on wound maturation**

20 To further clarify the effect of Dectin-2 on late-phase events in wound healing, we examined
21 the effect of Dectin-2 deficiency on collagen deposition and matrix metalloproteinase (MMP)
22 expression. As shown in Figure 6a, the content of hydroxyproline, a collagen-specific amino

1 acid, was significantly increased in Dectin-2-deficient mice compared with WT mice.
2 Additionally, the COL3A1-to-COL1A1 ratio tended to be lower in Dectin-2KO mice
3 compared with WT mice (Figure 6b). Transforming growth factor (TGF)- β 1 expression was
4 also increased in Dectin-2KO compared with WT mice (Figure 6c). MMP-2 and MMP-8
5 expression levels and the neutrophil elastase activity level were markedly decreased in
6 Dectin-2-KO compared with WT mice (Figure 6d and e).

7

8

9

10

11

12

13

14

1 DISCUSSION

2 In the current study, we demonstrated that Dectin-1 deficiency impaired wound healing while
3 Dectin-1 activation accelerated wound healing through promoting early-phase neutrophil
4 accumulation. However, Dectin-2 was involved in the prolonged neutrophilic inflammatory
5 response that is associated with NET accumulation. Additionally, Dectin-2 activation delayed
6 wound healing and attenuated both collagen synthesis and TGF- β expression. Recently, we
7 demonstrated that Dectin-2-mediated signaling delayed wound healing by prolonging
8 neutrophilic responses with NETosis (Miura et al., 2019). However, the effect of Dectin-1-
9 mediated signaling on wound healing was unknown. Thus, to our best knowledge, no studies
10 have previously reported the involvement of Dectin-1 and Dectin-2 in the regulation of skin
11 wound healing in distinct ways, especially in the neutrophil response.

12 Both Dectin-1 and Dectin-2 are known to be expressed on keratinocytes, dendritic cells,
13 Langerhans cells, macrophages, and neutrophils (van den Berg et al., 2014, Brasch et al.,
14 2014, Taylor et al., 2007, Taylor et al., 2005). To our knowledge previously unreported that
15 these CLRs are also expressed on fibroblasts. Thus, both Dectin-1 and Dectin-2 are likely to
16 be similarly expressed on recruited leukocytes and fibroblasts. However, Taylor and co-
17 workers (Taylor et al., 2005) have previously revealed that Dectin-1 is expressed at high
18 levels on early inflammatory monocytes, whereas Dectin-2 is expressed on migrated
19 inflammatory monocytes in the late phases of wound healing. Taylor et al. (2005) also
20 detected high levels of Dectin-1 expression on the surfaces of tissue-resident macrophages
21 and resident peritoneal macrophages, whereas Dectin-2 expression was very low in these
22 resident cells. In the present study, in the early inflammatory phase, we found that the

1 proportions of Dectin-1- and Dectin-2-expressing macrophages were $30.2\% \pm 0.8\%$ and
2 $19.3 \pm 1.6\%$, respectively. Thus, these data suggest that Dectin-1 may be highly expressed on
3 early inflammatory macrophages and skin tissue-resident macrophages.

4 Both Dectin-1 and Dectin-2 play central roles in host defense against a fungal infection
5 through recognition of β -1,3-glucan and high-mannose structures, respectively (Gantner et al.,
6 2003, McGreal et al., 2006). However, it remains unclear whether vimentin, an endogenous
7 binding protein for Dectin-1 (Thiagarajan et al., 2013), and β -glucuronidase, an endogenous
8 binding protein for Dectin-2 (Mori et al., 2017), are involved in the induction of inflammatory
9 responses after interacting with their receptors. In this study, vimentin and β -glucuronidase
10 were detected near Dectin-1- and Dectin-2-expressing cells. Consistent with this possibility,
11 experiments with reporter cells revealed that the supernatants of wounded tissues activate
12 Dectin-2-mediated but not Dectin-1-mediated signaling. Thus, our findings suggest that some
13 endogenous ligands such as β -glucuronidase may be involved in Dectin-2-mediated
14 responses. The supernatants from wounds did not activate Dectin-1 reporter cells in this
15 study. Previously, Xu and co-workers demonstrated that secreted forms of vimentin are
16 structurally different from non-secreted forms (Xu et al., 2004), which suggests that secreted
17 vimentin, despite being a putative Dectin-1 ligand, may interact less readily with Dectin-1 in
18 wounded tissue. However, it cannot be ruled out that this putative Dectin-1 ligand may simply
19 be secreted for a very short time after wounding.

20 We present evidence indicating that Dectin-1 regulates early-phase neutrophilic
21 responses, which are dependent on KC and MIP-2 production, whereas Dectin-2 is involved
22 in regulating late-phase neutrophilic responses, which are associated with these chemokines

1 and TNF- α and IL-17A. In a previous study using a keratitis mouse model, β -glucan from
2 *Aspergillus fumigatus* was shown to stimulate Dectin-1 signaling in resident corneal
3 macrophages, thereby accelerating neutrophil recruitment by inducing KC production (Leal et
4 al., 2010). Additionally, Fan et al. (2019) recently demonstrated that Dectin-1 on
5 macrophages contributes to early phase neutrophil recruitment, which is associated with
6 increased KC production, and that Dectin-1 expression levels subsequently decline to baseline
7 levels within 72 h after myocardial ischemia–reperfusion injury. Considered collectively, the
8 available findings suggest that Dectin-1 expressed on resident cells such as macrophages may
9 largely contribute to early phase neutrophil accumulation by sensing early damage signals and
10 inducing chemokine production.

11 The current study indicated that late-phase neutrophilic responses and NET formation
12 are attenuated under Dectin-2-deficiency. Dectin-2 is strongly expressed on migrated
13 inflammatory monocytes (Taylor et al., 2005), and macrophages are maintained at infarcted
14 sites for 7 days after myocardial infarction (Yan et al., 2017). Consistent with these
15 observations, we also observed that low but significant levels of Dectin-2 were detected until
16 day 7 after wounding. Because α -mannan induced late-phase neutrophilic responses, it is
17 likely that β -glucuronidase from damaged tissues is involved in similar responses.

18 Additionally, TNF- α and IL-17A synthesis were significantly higher in the late phase after α -
19 mannan treatment. Both TNF- α and IL-17A are well-known inducers of neutrophil
20 recruitment (Maher et al., 2013) and triggers of excessive NETosis (Khandpur et al., 2013),
21 although TNF- α is also involved in the disappearance of neutrophils through apoptosis
22 (Degterev and Yuan, 2008). The decrease in early neutrophil apoptosis that is associated with

1 reduced TNF- α production is involved in prolonging neutrophil infiltration and enhancing
2 NETs (Gray et al., 2018). Thus, in the present study, the failure of neutrophils to disappear
3 might be caused by their attenuated apoptosis in the early phase and might also be involved in
4 the NETs through TNF- α and IL-17A. Consistent with this possibility, our previous study
5 reported prolonged neutrophil accumulation and a corresponding reduction in neutrophil
6 apoptosis in wound tissues in mice that were deficient in NKT cells (Tanno et al., 2017).

7 Taylor and coworkers showed that both complement and Dectin-1 are considered to be
8 “*primary pathogen recognition systems*” because both are characterized by links between
9 pathogens and leukocytes in the immune responses to fungal infection (McDonald et al.,
10 2012, Taylor et al., 2007). In most fungal pathogens, the inner cell wall polysaccharides,
11 including β -glucan and chitin, are covered by outer cell wall polysaccharides such as
12 mannans, which are accordingly recognized by CLRs, leading to the development of immune
13 responses (Erwig and Gow, 2016). The exposure condition for β -glucans on the surface is
14 different between yeasts and hyphae of *Candida albicans*. When surface polysaccharide
15 structures change from those of mildly virulent yeasts to those of highly virulent hyphae
16 depending on the invasion status in the host, the resulting change in the access of Dectin-1 to
17 the inner β -glucan structures may affect the neutrophilic responses (Gow et al., 2011).
18 Additionally, immune responses became more pronounced upon exposure of the host PRRs to
19 β -glucan as opposed to α -mannan (Erwig and Gow, 2016, Netea et al., 2006). In the present
20 study, we demonstrated that Dectin-1 expression increases quite rapidly, enabling it to play
21 major roles in the regulation of early phase neutrophil accumulation. Thus, Dectin-1 could be
22 considered to be a central player in the early phase of wound healing through its direct

1 interaction with an unknown putative endogenous ligand such as vimentin (Thiagarajan et al.,
2 2013) as well as with exogenous ligands that are derived from resident fungi such as β -glucan
3 (Gao et al. 2010). Previously, Mor-Vaknin et al. (Mor-Vaknin et al., 2003) revealed that
4 vimentin is secreted from activated macrophages upon stimulation with TNF- α . Our previous
5 study indicated that TNF- α is released shortly after wounding and that it promotes
6 inflammatory leukocyte recruitment (Kanno et al., 2011). Considered collectively, these
7 findings suggest that a regulatory mechanism that is promoted by TNF- α may be involved in
8 the early events of wound healing after being triggered by a Dectin-1-dependent signaling
9 pathway.

10 In the current study, Dectin-1 expression quickly decreased to baseline levels beginning
11 12 h after wounding, whereas Dectin-2 expression continued to gradually increase during this
12 period. It has been reported that Dectin-1 and Dectin-2 are not detected at the same time
13 points, and that Dectin-2 expression is up-regulated in monocytes/macrophages under Dectin-
14 1-deficient conditions (Taylor et al., 2005). Additionally, Dectin-2 usually forms heterodimers
15 with MCL to enable more effective recognition of their ligands (Zhu et al., 2013), and these
16 heterodimers act to inhibit Dectin-1 signaling via Mincle, another member of the CLRs
17 (Wevers et al., 2014). Thus, in the current model, cross-regulation between Dectin-1 and
18 Dectin-2 may affect each of their expressions, and the presence of the Dectin-2-MCL
19 complex may contribute to the quick decrease in Dectin-1 expression through a direct or
20 indirect mechanism.

21 In this study, we found that NETs reached their peak level on day 3 in a Dectin-2-
22 dependent, but not Dectin-1-dependent, manner during natural wound healing in absence of

1 exogenous ligands. Previously, Wong et al. (Wong et al., 2015) revealed that NETs are
2 mediated by peptidylarginine deiminase 4 (PAD4), a calcium-dependent enzyme, during
3 natural wound healing (Luo et al., 2006). Calcium dependence was also reported in Dectin-2
4 binding to its ligand (Sato et al., 2006). In agreement with these observations, calcium flux
5 was reported to be necessary for efficient NETs (Gupta et al., 2014), and NETosis was
6 reported to be induced by incubation with ionomycin, a calcium ionophore (Wong et al.,
7 2015). In previous studies, wound closure was accelerated, but dermal healing was not
8 affected by partial depletion of neutrophils by approximately 80% for 2 days (Dovi et al.,
9 2003). However, in the present study, complete neutrophil depletion resulted in a significant
10 reduction of NETs formation and an acceleration of wound closure, which suggests that
11 NETs-forming neutrophils may be involved in interference with the wound healing process,
12 including that in dermis.

13 We also observed that DNA in the NETs plays a suppressive role as evidenced by the
14 finding that DNase I treatment promotes wound closure under both natural and α -mannan-
15 treated conditions. Similar findings have been reported previously (Wong et al., 2015). These
16 results suggest that DNA or its associated enzymes including elastase (Urban et al., 2009)
17 may be involved in the suppressive effect of NETs against wound healing. Neutrophil
18 elastase, which has been reported to bind to DNA in NETs (Papayannopoulos et al., 2010),
19 may play a role in this suppressive effect because, in our recent study, treatment with
20 neutrophil elastase improved the delayed wound healing caused by activation of Dectin-2
21 signals (Miura et al., 2019). Consistent with this possibility, in the present study, lower levels
22 of neutrophil elastase were detected in Dectin-2KO mice compared with WT mice.

1 Additionally, MMP-8 expression in wound tissues was also lower in Dectin-2KO mice.
2 Considered collectively, our current results suggest that some MMPs may be involved in late-
3 phase regulation of wound healing via a Dectin-2-dependent mechanism.

4 Scarring in the skin after trauma or surgery has been a major medical problem, and the
5 mechanisms of scarring have received much attention. Novel approaches for keloids and
6 hypertrophic scars seek to treat these scar tissues as chronic inflammatory disorders of the
7 skin (Gauglitz et al., 2011, Ogawa, 2017). High levels of TGF- β 1, which is a downstream
8 factor in inflammation, are detected at scar tissues, and markedly improved scarring is
9 reported under TGF- β 1-deficient conditions (Ferguson and O’Kane, 2004). TGF- β 1 is well
10 known as a promoting factor for collagen synthesis from fibroblasts and also contributes to
11 collagen-type transition from immature type III collagen (encoded by *COL3A1*) to mature
12 type I collagen (encoded by *COL1A1*) (Kim et al., 2018). For a long time, the detailed
13 mechanisms of scarring have remained unclear because the mechanisms inhibiting the healing
14 process have not been elucidated. In this study, TGF- β synthesis and collagen-type transition
15 from COL1A3 to COL1A1 were promoted under Dectin-2-deficient conditions. These results
16 suggest that Dectin-2-dependent signaling may prevent excessive collagen deposition, which
17 leads to scar formation, through regulating TGF- β and collagen-type transition.

18 We also observed delayed wound closure in WT mice treated with α -mannan, which was
19 accompanied by prolonged neutrophilic inflammation and TNF- α production, compared with
20 those treated with dZymosan or vehicle control. Previously, we demonstrated that inoculation
21 of *Pseudomonas aeruginosa* at wounded skin accelerated re-epithelialization and
22 neovascularization on day 3 as well as local infiltration of neutrophils, though no significant

1 acceleration of wound healing was detected on days 7 and 10 (Kanno et al., 2011). In
2 addition, high concentration of TNF- α , mainly derived from neutrophils, were detected from 6
3 hours to day 7 after this bacterial inoculation. Thus, considering our current and previous
4 findings collectively, TNF- α might play a promoting role in the early phase and inhibitory
5 role in the late phase of wound healing. Further investigations are necessary to address this
6 unsolved issue.

7 In conclusion, the current study may provide a new insight into how Dectin-2 helps to
8 prevent an excessive wound healing response, followed by scar formation, by playing a key
9 role in negative regulation of the wound healing response. This suggests a possible target for
10 developing novel therapies to treat chronic wounds, such as diabetic leg ulcers, and to prevent
11 keloids. These points are summarized in Supplementary Figure S8. Additionally, Dectin-1
12 could be another target molecule for developing novel therapies to accelerate wound healing
13 by promoting the inflammatory response.

14

15

16

17

18

19

20

21

22

1 MATERIALS AND METHODS

2 An extended description of our materials and methods can be found in the Supplementary
3 Materials and Methods online.

4

5 Mice

6 Dectin-1 KO mice were generated by homologous recombination of the *Clec7a* gene as
7 described previously (Saijo and Iwakura, 2011) and backcrossed to C57BL/6 mice for eight
8 generations. Dectin-2 gene-disrupted (knockout [KO]) mice were generated by homologous
9 recombination of the *Clec4n* gene as described previously (Saijo et al., 2010) and backcrossed
10 to C57BL/6 mice for seven generations or for more than eight generations. CARD9 KO mice
11 were generated and established as described previously (Hara et al., 2007) and backcrossed to
12 C57BL/6 mice for more than eight generations. Wild-type (WT) littermate mice of Dectin-
13 2KO mice were used as controls for seven generations. Except for experiments with Dectin-
14 2KO mice that were established over seven generations, C57BL/6 mice purchased from
15 CLEA Japan (Tokyo, Japan) were used as WT control. All mice were kept under specific
16 pathogen-free conditions in the Institute for Animal Experimentation, Tohoku University
17 Graduate School of Medicine (Sendai, Japan).

18

19 Wound creation and tissue collection

20 Wound creation and tissue collection were performed as described in the Supplementary
21 Materials and Methods.

22

1 **Treatment with dZymosan (zymosan depleted) or α -mannan**

2 Treatment with dZymosan (zymosan depleted) or α -mannan were performed as described in
3 the Supplementary Materials and Methods.

4

5 **Data availability statement**

6 No data sets were generated or analyzed during this study.

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

1 **CONFLICT OF INTEREST**

2 The authors state that there are no conflicts of interest.

3

4 **ACKNOWLEDGMENTS**

5 We thank Dr. Sho Yamasaki (Department of Molecular Immunology, Research Institute for
6 Microbial Diseases, Osaka University) for providing us with Dectin-1 and Dectin-2 reporter
7 cells and Dr. Hiromitsu Hara (Department of Immunology, Graduate School of Medical and
8 Dental Sciences, Kagoshima University) for providing us with the CARD9KO mice.

9 This work was supported in part by a Grant-in-Aid for Scientific Research (C)
10 (18K09473), Grant-in-Aid for Scientific Research (B) (19H03812), a Grant-in-Aid for
11 Challenging Exploratory Research (19K22649), and a Grant-in-Aid for Young Scientists
12 (19K19494) from the Ministry of Education, Culture, Sports, Science and Technology of
13 Japan.

14

15 **AUTHOR CONTRIBUTIONS**

16 Conceptualization: KY, EK, MT, KK; Data curation: KY, EK, HT, KK; Formal
17 Analysis: KY, EK, HT, AY, YK; Funding Acquisition: EK, MT, MT, KK; Investigation: KY,
18 HT, TM, NT, MS, JK, KS, YS, MN, YG, KI; Methodology: KY, HT, JK, KS, YI; Project
19 Administration: KY, EK, KK; Resources: KY, EK, HT, SS, YI, KK; Supervision: EK, MT,
20 KK; Validation: KY, EK, HT, KK; Visualization: TK, EK, MT, KK; Writing-Original
21 Draft Preparation: KY, EK, KK; Writing-Review and Editing: KY, EK, and KK.

22

1 **REFERENCES**

2 van den Berg, L.M., Zijlstra-Willems, E.M., Richters, C.D., Ulrich, M.M.W., Geijtenbeek,

3 **T.B.H. Dectin-1 activation induces proliferation and migration of human**

4 **keratinocytes enhancing wound re-epithelialization.** Cell. Immunol. 2014;289(1–

5 2):49–54

6

7 Brasch, J., Mörig, A., Neumann, B., Proksch, E. **Expression of antimicrobial peptides and**

8 **toll-like receptors is increased in tinea and pityriasis versicolor.** Mycoses.

9 2014;57(3):147–52

10

11 Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D.S. et al.

12 **Neutrophil extracellular traps kill bacteria.** Science. 2004;303(5663):1532–5

13

14 Degterev, A., Yuan, J. **Expansion and evolution of cell death programmes.** Nat. Rev. Mol.

15 Cell Biol. 2008;9(5):378–90

16

17 Dovi, J.V., He, L-K., DiPietro, L.A. **Accelerated wound closure in neutrophil-depleted**

18 **mice.** J. Leukoc. Biol. 2003;73(4):448–55

19

20 Erwig, L.P., Gow, N.A.R. **Interactions of fungal pathogens with phagocytes.** Nat. Rev.

21 Microbiol. 2016;14(3):163–76

22 Fan, Q., Tao, R., Zhang, H., Xie, H., Lu, L., Wang, T. et al. **Dectin-1 contributes to**

- 1 **myocardial ischemia/reperfusion injury by regulating macrophage**
2 **polarization and neutrophil infiltration.** *Circulation.* 2019;139(5):663–78
3
- 4 Ferguson, M.W.J., O’Kane, S. **Scar-free healing: from embryonic mechanisms to adult**
5 **therapeutic intervention.** *Philos. Trans. R. Soc. Lond. B. Biol. Sci.*
6 2004;359(1445):839–50
7
- 8 Gantner, B.N., Simmons, R.M., Canavera, S.J., Akira, S., Underhill, D.M. **Collaborative**
9 **induction of inflammatory responses by dectin-1 and Toll-like receptor 2.** *J. Exp.*
10 *Med.* 2003;197(9):1107–17
11
- 12 Gao, Z., Perez-Perez, G.I., Chen, Y., Blaser, M.J. **Quantitation of major human cutaneous**
13 **bacterial and fungal populations.** *J. Clin. Microbiol.* 2010;48(10):3575–81
14
- 15 Gauglitz, G.G., Korting, H.C., Pavicic, T., Ruzicka, T., Jeschke, M.G. **Hypertrophic**
16 **scarring and keloids: pathomechanisms and current and emerging treatment**
17 **strategies.** *Mol. Med. Camb. Mass.* 2011;17(1–2):113–25
18
- 19 Girardin, S.E., Sansonetti, P.J., Philpott, D.J. **Intracellular vs extracellular recognition of**
20 **pathogens--common concepts in mammals and flies.** *Trends Microbiol.*
21 2002;10(4):193–9
22

- 1 Gow, N.A.R., van de Veerdonk, F.L., Brown, A.J.P., Netea, M.G. **Candida albicans**
2 **morphogenesis and host defence: discriminating invasion from colonization.**
3 Nat. Rev. Microbiol. 2011;10(2):112–22
4
- 5 Gray, R.D., Hardisty, G., Regan, K.H., Smith, M., Robb, C.T., Duffin, R. et al. **Delayed**
6 **neutrophil apoptosis enhances NET formation in cystic fibrosis.** Thorax.
7 2018;73(2):134–44
8
- 9 Gupta, A.K., Giaglis, S., Hasler, P., Hahn, S. **Efficient neutrophil extracellular trap**
10 **induction requires mobilization of both intracellular and extracellular calcium**
11 **pools and is modulated by cyclosporine A.** PloS One. 2014;9(5):e97088
12
- 13 Hara, H., Ishihara, C., Takeuchi, A., Imanishi, T., Xue, L., Morris, S.W. et al. **The adaptor**
14 **protein CARD9 is essential for the activation of myeloid cells through ITAM-**
15 **associated and Toll-like receptors.** Nat. Immunol. 2007;8(6):619–29
16
- 17 Kanno, E., Kawakami, K., Ritsu, M., Ishii, K., Tanno, H., Toriyabe, S. et al. **Wound healing**
18 **in skin promoted by inoculation with Pseudomonas aeruginosa PAO1: The**
19 **critical role of tumor necrosis factor- α secreted from infiltrating neutrophils.**
20 Wound Repair Regen. 2011;19(5):608–21
21
- 22 Kanno, E., Kawakami, K., Tanno, H., Suzuki, A., Sato, N., Masaki, A. et al. **Contribution of**

- 1 **CARD9-mediated signalling to wound healing in skin.** *Exp. Dermatol.*
2 2017;26(11):1097–104
3
- 4 Khandpur, R., Carmona-Rivera, C., Vivekanandan-Giri, A., Gizinski, A., Yalavarthi, S.,
5 Knight, J.S. et al. **NETs are a source of citrullinated autoantigens and stimulate**
6 **inflammatory responses in rheumatoid arthritis.** *Sci. Transl. Med.*
7 2013;5(178):178ra40
8
- 9 Kim, K.K., Sheppard, D., Chapman, H.A. **TGF- β 1 signaling and tissue fibrosis.** *Cold*
10 Spring Harb. Perspect. Biol. 2018;10(4)
11
- 12 Kolaczowska, E., Kubes, P. **Neutrophil recruitment and function in health and**
13 **inflammation.** *Nat. Rev. Immunol.* 2013;13(3):159–75
14
- 15 Leal, S.M., Cowden, S., Hsia, Y-C., Ghannoum, M.A., Momany, M., Pearlman, E. **Distinct**
16 **roles for Dectin-1 and TLR4 in the pathogenesis of *Aspergillus fumigatus***
17 **keratitis.** *PLoS Pathog.* 2010;6:e1000976
18
- 19 Luo, Y., Arita, K., Bhatia, M., Knuckley, B., Lee, Y-H., Stallcup, M.R. et al. **Inhibitors and**
20 **inactivators of protein arginine deiminase 4: functional and structural**
21 **characterization.** *Biochemistry.* 2006;45(39):11727–36
22

- 1 Maher, B.M., Mulcahy, M.E., Murphy, A.G., Wilk, M., O’Keeffe, K.M., Geoghegan, J.A. et
2 al. **Nlrp-3-driven interleukin 17 production by $\gamma\delta$ T cells controls infection**
3 **outcomes during *Staphylococcus aureus* surgical site infection.** *Infect. Immun.*
4 2013;81(12):4478–89
- 5
- 6 McDonald, J.U., Rosas, M., Brown, G.D., Jones, S.A., Taylor, P.R. **Differential**
7 **dependencies of monocytes and neutrophils on dectin-1, dectin-2 and**
8 **complement for the recognition of fungal particles in inflammation.** *PloS One.*
9 2012;7(9):e45781
- 10
- 11 McGreal, E.P., Rosas, M., Brown, G.D., Zamze, S., Wong, S.Y.C., Gordon, S. et al. **The**
12 **carbohydrate-recognition domain of Dectin-2 is a C-type lectin with specificity**
13 **for high mannose.** *Glycobiology.* 2006;16(5):422–30
- 14
- 15 Miura, T., Kawakami, K., Kanno, E., Tanno, H., Tada, H., Sato, N. et al. **Dectin-2-mediated**
16 **signaling leads to delayed skin wound healing through enhanced**
17 **neutrophilic inflammatory response and neutrophil extracellular trap**
18 **formation.** *J. Invest. Dermatol.* 2019;139(3):702–11
- 19
- 20 Mori, D., Shibata, K., Yamasaki, S. **C-type lectin receptor dectin-2 binds to an**
21 **endogenous protein β -glucuronidase on dendritic cells.** *PLOS ONE.*
22 2017;12(1):e0169562

- 1
- 2 Mor-Vaknin, N., Punturieri, A., Sitwala, K., Markovitz, D.M. **Vimentin is secreted by**
- 3 **activated macrophages.** Nat. Cell Biol. 2003;5(1):59–63
- 4
- 5 Netea, M.G., Gow, N.A.R., Munro, C.A., Bates, S., Collins, C., Ferwerda, G. et al. **Immune**
- 6 **sensing of *Candida albicans* requires cooperative recognition of mannans and**
- 7 **glucans by lectin and Toll-like receptors.** J. Clin. Invest. 2006;116(6):1642–50
- 8
- 9 Ogawa, R. **Keloid and hypertrophic scars are the result of chronic inflammation in**
- 10 **the reticular dermis.** Int. J. Mol. Sci. 2017;18(3) pii: E606.
- 11
- 12 Ohtsuka, M., Arase, H., Takeuchi, A., Yamasaki, S., Shiina, R., Suenaga, T. et al. **NFAM1,**
- 13 **an immunoreceptor tyrosine-based activation motif-bearing molecule that**
- 14 **regulates B cell development and signaling.** Proc. Natl. Acad. Sci.
- 15 2004;101(21):8126–31
- 16
- 17 de Oliveira, S., Rosowski, E.E., Huttenlocher, A. **Neutrophil migration in infection and**
- 18 **wound repair: going forward in reverse.** Nat. Rev. Immunol. 2016;16(6):378–91
- 19
- 20 Palma, A.S., Feizi, T., Zhang, Y., Stoll, M.S., Lawson, A.M., Díaz-Rodríguez, E. et al.
- 21 **Ligands for the β -glucan receptor, dectin-1, assigned using “designer”**
- 22 **microarrays of oligosaccharide probes (neoglycolipids) generated from**

- 1 **glucan polysaccharides.** J. Biol. Chem. 2006;281(9):5771–9
- 2
- 3 Papayannopoulos, V., Metzler, K.D., Hakkim, A., Zychlinsky, A. **Neutrophil elastase and**
- 4 **myeloperoxidase regulate the formation of neutrophil extracellular traps.** J. Cell
- 5 Biol. 2010;191(3):677–91
- 6
- 7 Pasparakis, M., Haase, I., Nestle, F.O. **Mechanisms regulating skin immunity and**
- 8 **inflammation.** Nat. Rev. Immunol. 2014;14(5):289–301
- 9
- 10 Saijo, S., Ikeda, S., Yamabe, K., Kakuta, S., Ishigame, H., Akitsu, A. et al. **Dectin-2**
- 11 **recognition of alpha-mannans and induction of Th17 cell differentiation is**
- 12 **essential for host defense against *Candida albicans*.** Immunity. 2010;32(5):681–91
- 13
- 14 Saijo, S., Iwakura, Y. **Dectin-1 and Dectin-2 in innate immunity against fungi.** Int.
- 15 Immunol. 2011;23(8):467–72
- 16
- 17 Sato, K., Yang, X., Yudate, T., Chung, J-S., Wu, J., Luby-Phelps, K. et al. **Dectin-2 is a**
- 18 **pattern recognition receptor for fungi that couples with the Fc receptor gamma**
- 19 **chain to induce innate immune responses.** J. Biol. Chem. 2006;281(50):38854–66
- 20
- 21 Tanno, H., Kawakami, K., Kanno, E., Suzuki, A., Takagi, N., Yamamoto, H. et al. **Invariant**
- 22 **NKT cells promote skin wound healing by preventing a prolonged neutrophilic**

- 1 **inflammatory response.** *Wound Repair Regen.* 2017;25(5):805–15
- 2
- 3 Taylor, P.R., Reid, D.M., Heinsbroek, S.E.M., Brown, G.D., Gordon, S., Wong, S.Y.C.
- 4 **Dectin-2 is predominantly myeloid restricted and exhibits unique activation-**
- 5 **dependent expression on maturing inflammatory monocytes elicited in vivo.** *Eur.*
- 6 *J. Immunol.* 2005;35(7):2163–74
- 7 Taylor, P.R., Tsoni, S.V., Willment, J.A., Dennehy, K.M., Rosas, M., Findon, H. et al.
- 8 **Dectin-1 is required for beta-glucan recognition and control of fungal infection.**
- 9 *Nat. Immunol.* 2007;8(1):31–8
- 10
- 11 Thiagarajan, P.S., Yakubenko, V.P., ElSORI, D.H., Yadav, S.P., Willard, B., Tan, C.D. et al.
- 12 **Vimentin is an endogenous ligand for the pattern recognition receptor Dectin-1.**
- 13 *Cardiovasc. Res.* 2013;99(3):494–504
- 14
- 15 Thomas, G.M., Carbo, C., Curtis, B.R., Martinod, K., Mazo, I.B., Schatzberg, D. et al.
- 16 **Extracellular DNA traps are associated with the pathogenesis of TRALI in**
- 17 **humans and mice.** *Blood.* 2012;119(26):6335–43
- 18
- 19 Urban, C.F., Ermert, D., Schmid, M., Abu-Abed, U., Goosmann, C., Nacken, W. et al.
- 20 **Neutrophil extracellular traps contain calprotectin, a cytosolic protein**
- 21 **complex involved in host defense against *Candida albicans*.** *PLoS Pathog.*
- 22 2009;5(10) Available from:

1 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763347/>

2

3 Wevers, B.A., Kaptein, T.M., Zijlstra-Willems, E.M., Theelen, B., Boekhout, T., Geijtenbeek,
4 T.B.H. et al. **Fungal engagement of the C-type lectin mincle suppresses dectin-1-**
5 **induced antifungal immunity.** Cell Host Microbe. 2014;15(4):494–505

6

7 Wilgus, T.A., Roy, S., McDaniel, J.C. **Neutrophils and wound repair: Positive actions**
8 **and negative reactions.** Adv. Wound Care. 2013;2(7):379–88

9

10 Wong, S.L., Demers, M., Martinod, K., Gallant, M., Wang, Y., Goldfine, A.B. et al. **Diabetes**
11 **primes neutrophils to undergo NETosis, which impairs wound healing.** Nat.
12 Med. 2015;21(7):815–9

13

14 Xu, B., deWaal, R.M., Mor-Vaknin, N., Hibbard, C., Markovitz, D.M., Kahn, M.L. **The**
15 **endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin**
16 **in the blood vasculature.** Mol. Cell. Biol. 2004;24(20):9198–206

17

18 Yan, X., Zhang, H., Fan, Q., Hu, J., Tao, R., Chen, Q. et al. **Dectin-2 deficiency modulates**
19 **Th1 differentiation and improves wound healing after myocardial infarction.**
20 Circ. Res. 2017;120(7):1116–29

21

22 Zhu, L-L., Zhao, X-Q., Jiang, C., You, Y., Chen, X-P., Jiang, Y-Y. et al. **C-type lectin**

1 **receptors Dectin-3 and Dectin-2 form a heterodimeric pattern-recognition**
2 **receptor for host defense against fungal infection.** *Immunity*. 2013;39(2):324–34

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

1 **FIGURE LEGENDS**

2 **Figure 1. Dectin-1 and Dectin-2 levels were increased in the skin after wound creation**

3 (a) Dectin-1 and Dectin-2 expression in the wounded tissues at the specified time points. Six
4 wounds were created in one mouse, which were combined as one sample, and three mice were
5 analyzed in each group. (b) Immunohistochemistry of Dectin-1, vimentin as a Dectin-1
6 ligand, Dectin-2, and β -glucuronidase as a Dectin-2 ligand in wounded skin at day 1 after
7 wound creation and in unwounded skin (0 h). Arrowheads indicate Dectin-1- and Dectin-2-
8 positive cells, respectively. Scale bar = 20 μ m. (c) Flow cytometric analysis of Dectin-1- and
9 Dectin-2-expressing cells (neutrophils, macrophages, and fibroblasts) at 24 hours after wound
10 creation. Six wounds were created in one mouse, which were combined as one sample, and
11 three mice were analyzed in each group. Each column represents the mean \pm standard
12 deviation. * $p < 0.05$, ** $p < 0.01$

13

14 **Figure 2. Effects of Dectin-1 and Dectin-2 deficiency on wound healing and neutrophil** 15 **accumulation**

16 Wounds were created on the backs of mice. (a) Representative photographs of wounds on
17 days 0 and 5. (b) Percentage of wound closure was evaluated on day 5 (30 wounds/group). (c)
18 Representative histological views of skin wounds are shown. Arrowheads and arrows indicate
19 the re-epithelialized leading edges and the original wound edges, respectively. The re-
20 epithelialization ratio on day 5 is shown (6 wounds/group). Scale bar = 500 μ m. (d) The
21 number of epithelial cells stained with PCNA antibody on day 5. Arrowheads and the dotted
22 line indicate PCNA-positive cells and the border between epidermis and dermis, respectively.

1 The epithelial cell density/mm² was determined by counting the positive cells (5
2 wounds/group). Scale bar = 20 μm. (e) The number of microvessels stained with anti-CD31
3 antibody on day 5. Arrowheads indicate CD31-positive microvessels. The vascular
4 density/mm² was determined by counting the positive vessels (5 wounds/group). Scale bar =
5 20 μm. (f) The number of myofibroblasts stained with α-SMA antibody on day 5. Arrowheads
6 indicate α-SMA-positive cells. The myofibroblast density/mm² was determined by counting
7 the positive cells (5 wounds/group). Scale bar = 20 μm. (g) The number of neutrophils in the
8 wounded tissue was analyzed at 6 hours and on day 5 after wound creation. Six wounds were
9 created in one mouse, which were combined into one sample, and five mice were analyzed in
10 each group. Each column represents the mean ± standard deviation. **p* < 0.05, ***p* < 0.01

11

12 **Figure 3. Effects of topical administration of dZymosan or α-mannan on wound healing**

13 Wounded WT mice received dZymosan, α-mannan, or vehicle immediately after wounding.

14 (a) Representative photographs of wounds on days 0, 3, 5, and 7. (b) Percentage of wound
15 closure was evaluated on days 3, 5, and 7 (30 wounds/group). (c) Representative histological
16 views of skin wounds on day 5 are shown. Arrowheads and arrows indicate the re-
17 epithelialized leading edges and the original wound edges, respectively. The re-
18 epithelialization ratio on day 5 is shown (6 wounds/group). Scale bar = 500 μm. (d)

19 Hydroxyproline content on day 5 after wound creation. Six wounds were created in one
20 mouse, which were combined into one sample, and six mice were analyzed in each group. (e)

21 The number of epithelial cells stained with PCNA antibody on day 5. Arrowheads and the
22 dotted line indicate PCNA-positive cells and the border between the epidermis and dermis,

1 respectively. The epithelial cell density/mm² was determined by counting the positive cells (5
2 wounds/group). Scale bar = 20 μm. (f) The number of microvessels stained with anti-CD31
3 antibody on day 5. Arrowheads indicate CD31-positive microvessels. The vascular
4 density/mm² was determined by counting the positive vessels (5 wounds/group). Scale bar =
5 20 μm. (g) The number of myofibroblasts stained with α-SMA antibody on day 5.
6 Arrowheads indicate α-SMA-positive cells. The myofibroblast density/mm² was determined
7 by counting the positive cells (5 wounds/group). Scale bar = 20 μm. Each column represents
8 the mean ± standard deviation. **p* < 0.05, ***p* < 0.01

9

10 **Figure 4. Effects of topical dZymosan or α-mannan administration on the neutrophilic**
11 **inflammatory responses and NETosis**

12 Wounded WT mice received dZymosan, α-mannan, or vehicle immediately after wounding.
13 (a) The number of neutrophils in the wounded tissue was analyzed at 6, 12, and 24 hours and
14 on days 3, 5, and 7 after wound creation. Six wounds were created in one mouse, which were
15 combined into one sample, and five mice were analyzed in each group. (b) TNF-α, IL-17A,
16 CXCL1 (KC), and CXCL2 (MIP-2) levels in the wounded tissue homogenates were measured
17 at 6 h and on day 3. The dotted line indicates the baseline of the unwounded skin. Six wounds
18 were created in one mouse, which were combined into one sample, and five mice were
19 analyzed in each group. (c) NET formation at the wound sites of vehicle-, dZymosan- and α-
20 mannan-treated mice, evaluated on day 5 by immunofluorescence staining of Ly6G and Cit
21 H3. Scale bars = 16 μm

1 (d) Cit H3, H3, and GAPDH expression was analyzed by Western blotting. Six wounds were
2 created in one mouse, which were combined into one sample, and three mice were analyzed in
3 each group. (e) Quantification levels of Cit H3 compared to histone H3 were evaluated by
4 Western blotting analysis on day 5. (f) Quantification levels of Cit H3 compared to histone
5 H3 were evaluated using Western blotting analysis at 6 h. Six wounds were created in one
6 mouse, which were combined into one sample, and three mice were analyzed in each group.
7 Each column represents the mean \pm standard deviation. * $p < 0.05$, ** $p < 0.01$

8

9

10 **Figure 5. Effect of Dectin-1 and Dectin-2 deficiency, DNase, and neutrophil depletion on**
11 **NET formation**

12 (a) NET formation at wound sites of wounded WT mice that did not receive any treatment at
13 each of the specified time points. Cit H3, H3, and GAPDH expression was analyzed by
14 Western blotting (left). Quantification levels of Cit H3 compared to histone H3 were
15 evaluated using Western blotting (right). Six wounds were created in one mouse, which were
16 combined into one sample, and three mice were analyzed in each group. (b) Quantification
17 levels of Cit H3 compared to histone H3 at the wound sites of WT mice and Dectin-2KO
18 mice were evaluated on day 3. Six wounds were created in one mouse, which were combined
19 into one sample, and three mice were analyzed in each group. (c) Quantification levels of Cit
20 H3 compared to histone H3 at the wound sites of WT mice and Dectin-1KO mice were
21 evaluated on day 3. Six wounds were created in one mouse, which were combined into one
22 sample, and three mice were analyzed in each group. (d) WT mice were injected

1 intraperitoneally with DNase or vehicle from 1 day before wounding to 1 day before tissue
2 collection. Wounded WT mice received α -mannan or vehicle immediately after wounding.
3 The percentage of wound closure was evaluated on day 5 (18 wounds/group). (e) The
4 percentage of wound closure was evaluated on day 3 (18 wounds/group). (f) Quantification
5 levels of Cit H3 compared to histone H3 at the wound sites were evaluated on day 5. Six
6 wounds were created in one mouse, which were combined into one sample, and three mice
7 were analyzed in each group. (g) Wounds were created on the backs of mice and anti-Gr-1
8 monoclonal antibody or control IgG was injected intraperitoneally 1 day after wounding. The
9 percentage of wound closure was evaluated on day 3 (18 wounds/group). (h) Quantification
10 levels of Cit H3 compared to histone H3 at the wound sites were evaluated on day 3. Six
11 wounds were created in one mouse, which were combined into one sample, and three mice
12 were analyzed in each group. Each column represents the mean \pm standard deviation. * p <
13 0.05, ** p < 0.01

14

15 **Figure 6. Effect of Dectin-2 deficiency on wound maturation**

16 Wounds were created on the backs of Dectin-2-KO or WT mice. (a) Hydroxyproline content
17 in the wounded tissue was evaluated on day 10. Six wounds were created in one mouse,
18 which were combined into one sample, and six mice were analyzed in each group. (b) The
19 COL3A1-to-COL1A1 ratio in wounded tissues was evaluated on day 10. Six wounds were
20 created in one mouse, which were combined into one sample, and six mice were analyzed in
21 each group. (c) TGF- β 1 expression was evaluated on day 5. Six wounds were created in one
22 mouse, which were combined into one sample, and six mice were analyzed in each group. (d)

1 MMP-2 and MMP-8 expression was evaluated on day 10. Six wounds were created in one
2 mouse, which were combined into one sample, and six mice were analyzed in each group. (e)
3 Neutrophil elastase activity in the homogenized wound tissue was evaluated on day 3. Six
4 wounds were created in one mouse, which were combined into one sample, and five mice
5 were analyzed in each group. Each column represents the mean \pm standard deviation. * p <
6 0.05, ** p < 0.01

7

8

9

10

11

12

13


14

15


16

17


18




150x199mm (300 x 300 DPI)




175x228mm (300 x 300 DPI)




175x228mm (300 x 300 DPI)



175x199mm (300 x 300 DPI)



175x192mm (300 x 300 DPI)



150x122mm (300 x 300 DPI)

1 SUPPLEMENTARY MATERIALS AND METHODS

2 Mice

3 Dectin-1 KO mice were generated by homologous recombination of the *Clec7a* gene as
4 described previously (Saijo and Iwakura, 2011) and backcrossed to C57BL/6 mice for eight
5 generations. Dectin-2 gene-disrupted (knockout [KO]) mice were generated by homologous
6 recombination of the *Clec4n* gene as described previously (Saijo et al., 2010) and backcrossed
7 to C57BL/6 mice for seven generations or for more than eight generations. CARD9 KO mice
8 were generated and established as described previously (Hara et al., 2007) and backcrossed to
9 C57BL/6 mice for more than eight generations. Wild-type (WT) littermate mice of Dectin-
10 2KO mice were used as controls for seven generations. Except for experiments with Dectin-
11 2KO mice that were established over seven generations, C57BL/6 mice purchased from
12 CLEA Japan (Tokyo, Japan) were used as WT control. Male mice at 7 to 10 weeks of age
13 were used in the experiments. Food and water were available *ad libitum*. All mice were kept
14 under specific pathogen-free conditions in the Institute for Animal Experimentation, Tohoku
15 University Graduate School of Medicine (Sendai, Japan).

16

17 Wound creation and tissue collection

18 All wound creation was performed under anesthesia that was induced by an intraperitoneal
19 injection of 40 mg/kg sodium pentobarbital (Somnopentyl, Kyoritsu Seiyaku Corporation,
20 Tokyo, Japan), and sustained by inhalation anesthesia of isoflurane (Isoflurane, Mairan
21 Pharma, Osaka, Japan). The dorsal hair was shaved to fully expose the skin, which was then
22 rinsed with 70% ethanol. Six full-thickness wounds extending to the panniculus carnosus

1 were created on each mouse using a 3-mm diameter biopsy punch (Biopsy Punch, Kai
2 Industries Co., Ltd., Gifu, Japan) under sterile conditions. The wounds were covered with a
3 polyurethane film (Tegaderm Transparent Dressing, 3M Health Care, St. Paul, MN, USA) and
4 an elastic adhesive bandage (Hilate, Iwatsuki, Tokyo, Japan) as an occlusive dressing. The
5 day on which the wounds were made was day 0. At various time points, mice were sacrificed
6 and wound tissue was collected by excising the tissue using an 8-mm diameter biopsy punch.

7

8 **Treatment with dZymosan (zymosan depleted) or α -mannan**

9 dZymosan (zymosan depleted), which was prepared from *Saccharomyces cerevisiae* cell walls
10 treated with hot alkali to remove all their TLR-stimulating properties, was purchased from
11 Invivogen (San Diego, CA, USA) and diluted with phosphate buffered saline (PBS) at 0.5
12 mg/mL. Mannan from *Saccharomyces cerevisiae* (α -mannan) was purchased from Sigma-
13 Aldrich (St. Louis, MO, USA) and diluted with phosphate buffered saline (PBS) at 10
14 mg/mL. Wounds were created in accordance with the method described above, and
15 immediately after wounding, a 3- μ L suspension of dZymosan (2.5 μ g), α -mannan (30 μ g), or
16 PBS as a vehicle control was applied to the base of the wounds in WT, Dectin-1KO, or
17 Dectin-2KO mice.

18

19 **Administration of deoxyribonuclease (DNase) I**

20 DNase I, a deoxyribonuclease for single-stranded DNA and double-stranded DNA, was
21 purchased from FUJIFILM Wako Pure Chemical Co. (Osaka, Japan) and dissolved in normal
22 saline at a concentration of 250 U/mL. To inhibit single- and double-stranded DNA, WT mice

1 and WT mice treated with α -mannan were injected intraperitoneally with a 200 μ L suspension
2 of DNase I (50 U) each day from 1 day before wounding to 1 day before tissue collection. As
3 a control group for the relevant experiments, mice were injected with normal saline at the
4 same time points.

5

6 **Neutrophil depletion with anti-Gr-1 antibody**

7 Anti-Gr-1 monoclonal antibody was purified from hybridoma culture supernatants (clones
8 RB6-8C5) using a protein G column kit (Kirkegaard & Perry Laboratories, Gaithersburg, MD,
9 USA). This monoclonal antibody (Gr-1) completely depletes mouse neutrophils (Miura et al.,
10 2019). To neutralize the biological activity of neutrophils, mice were injected intraperitoneally
11 with 400 μ g of mAb at 24 hours after wounding. Rat IgG (ICN Pharmaceuticals, Aurora, OH,
12 USA) was used as a control antibody.

13

14 **Measurement of wound areas**

15 Wound areas were measured on digital images that were obtained with a digital camera (CX4;
16 Ricoh, Tokyo, Japan). After the wounds were created, photographs were taken of each wound
17 before dressing. At various time points, the polyurethane films were removed from the mice
18 and the wounds were photographed. Each wounded area was quantified by tracing its margin
19 and calculating the pixel area using AxioVision imaging software, release 4.6 (Carl Zeiss
20 Micro Imaging Japan, Tokyo, Japan). The percentage of wound closure was calculated using
21 the following formula: % wound closure = $(1 - \text{wound area at the indicated time point} /$
22 $\text{wound area 1 on day 0}) \times 100$.

1

2 **Analysis of hydroxyproline content**

3 Wounds were removed using an 8-mm diameter biopsy punch after mice were sacrificed, and
4 total wound hydroxyproline content was assayed. Briefly, all wound tissue was homogenized
5 and then hydrolyzed in 6N HCl for 21 hours at 120°C. The hydrolysate was neutralized with
6 NaOH. In the next step, 2-mL aliquots were analyzed calorimetrically for hydroxyproline
7 content adding 1 mL of 0.05 mol/L chloramine T (Nacalai Tesque, Kyoto, Japan), 1 mL of
8 3.15 mol/L perchloric acid (Nacalai Tesque), and 1 mL of 20% dimethylaminobenzaldehyde
9 (Nacalai Tesque). The optical densities of the samples were determined using a
10 spectrophotometer at 557 nm.

11

12 **Histology and immunohistochemistry**

13 The removed wound tissues were fixed with 4% paraformaldehyde-phosphate buffer solution
14 and embedded in paraffin. Sections were taken from the central portion of the wound and
15 stained with hematoxylin-eosin (HE) in accordance with the standard method. The extent of
16 re-epithelialization in each wound was measured in these HE-stained sections by measuring
17 the distance from the normal wound margin to the edge of the epithelium. The re-
18 epithelialization index was determined based on the percentage of new epithelium that was
19 present in the total wound.

20 For immunohistochemistry, after blocking with endogenous peroxidase using methanol/
21 hydrogen peroxide, the sections were incubated with 10% normal rabbit serum for 20 min to
22 block non-specific binding and then stained with anti-Dectin-1 Ab (dilution 1:25;

1 BioLegend, San Diego, CA, USA), anti-Dectin-2 Ab (dilution 1:100; Bio-Rad Laboratories,
2 Hercules, CA, USA), anti-Vimentin Ab (dilution 1:100; Abcam plc, Cambridge, UK), anti- β -
3 glucuronidase (dilution 1:100; Proteintech, Rosemont, IL, USA), anti-proliferating cell
4 nuclear antigen (PCNA) Ab (dilution 1:100; Agilent Technologies, Santa Clara, CA, USA),
5 anti- α -smooth muscle actin (α -SMA) Ab (dilution 1:300; Vector Laboratories, Inc.,
6 Burlingame, CA, USA), and anti-CD31 (PECAM-1) Ab (0.25 μ g/mL; Santa Cruz
7 Biotechnology, Santa Cruz, CA, USA). The sections were incubated with peroxidase-
8 conjugated secondary Ab (4 μ g/mL; Histofine Simple Stain MAX-PO, Nichirei Bioscience,
9 Tokyo, Japan).

10 Epithelial cell differentiation, vascular density in the granulation tissue, and
11 myofibroblast differentiation were determined by counting the number of PCNA-positive
12 epithelial cells, the number of CD31-positive vessels, and the number of α -SMA-positive
13 cells, respectively. All analyses were performed under blinded conditions.

14 For fluorescent immunostaining, the tissues were embedded in OCT compound (Sakura
15 Finetechnical Co., Tokyo, Japan) and quickly frozen. The sections were taken from the central
16 portion of the wound, blocked with 10% normal goat serum (Nichirei Bioscience, Tokyo,
17 Japan), and incubated with a primary Ab against citrullinated histone H3 (Cit H3) (rabbit
18 (0.04 μ g/mL; Abcam) and anti-Ly6G (rat) (clone 1A8, 5 μ g/mL; BioLegend) at 4°C
19 overnight, and then with Alexa 488-conjugated secondary Ab (anti-rabbit) (0.02 μ g/mL; Life
20 Technologies, Tokyo, Japan) and Alexa 555-conjugated secondary Ab (anti-rat) (0.02 μ g/mL;
21 Life Technologies) for 30 min at room temperature (RT). After the sections were covered with
22 mountant (VECTASHIELD[®] Hard Set Mounting Medium; Vector Laboratories, Inc.), images

1 were acquired by fluorescence microscopy (FSX100; Olympus, Tokyo, Japan).

2

3 **Preparation of leukocytes in the wound tissue**

4 Mice were sacrificed at 6, 12, or 24 hours or on days 3, 5, or 7 after wound creation. The
5 wound tissues were excised using a biopsy punch (8 mm in diameter) and teased apart using
6 stainless-steel mesh in RPMI 1640 medium (Nipro, Osaka, Japan) supplemented with 10 mM
7 HEPES, 10% fetal calf serum (FCS) (BioWest, Nuaille, France), 1 mg/mL collagenase, and 1
8 mg/mL hyaluronidase (Sigma-Aldrich). They were incubated for 2 hours at 37°C with
9 vigorous shaking. After incubation, the tissue fragments and most dead cells were removed by
10 passing the cells through a 70- μ m cell strainer (BD Falcon, Bedford, MA, USA). They were
11 then washed three times with 1% FCS RPMI 1640 medium and used as skin leukocytes for
12 flow cytometric analysis.

13

14 **Analysis of Dectin-1, 2-positive cells using flow cytometry**

15 The cells obtained from the wound tissues were stained with Pacific blue-anti-CD45
16 monoclonal antibody (mAb) (clone 30-F11, BioLegend), allophycocyanin cyanin 7
17 (APC/Cy7)-anti-Ly6G mAb (clone 1A8, BioLegend), phycoerythrin (PE)-anti-F4/80 mAb
18 (clone BM8, BioLegend), allophycocyanin (APC)-anti-CD140a mAb (clone APA5,
19 BioLegend), APC-anti-Dectin-1 mAb (clone RH1, BioLegend), and fluorescein
20 isothiocyanate (FITC)-anti-Dectin-2 mAb (clone KVa7-6E7, Miltenyi Biotec, Bergisch
21 Gladbach, Germany). Isotype-matched irrelevant IgG was used as the control staining.
22 Macrophages and neutrophils were identified as CD45⁺F4/80⁺ cells and CD45⁺Ly6G⁺ cells,

1 respectively. Fibroblasts were identified as CD45+CD140a+ cells. The stained cells were
2 analyzed using a BD FACS Canto II flow cytometer (BD Bioscience, San Jose, CA, USA).

3

4 **Analysis of leukocyte fraction using flow cytometry**

5 The cells obtained from wounded tissues were stained with Pacific blue-anti-CD45 mAb
6 (clone 30-F11, BioLegend), APC-anti-CD11b mAb (clone M1/70, BioLegend), APC/Cy7-
7 anti-Ly6G mAb (clone 1A8, BioLegend), and Alexa Fluor[®]488-anti-F4/80 mAb (clone BM8,
8 BioLegend). Isotype-matched irrelevant IgG was used for control staining. Macrophages and
9 neutrophils were identified as CD45+CD11b+F4/80+ cells and CD45+CD11b+Ly6G+ cells,
10 respectively. The stained cells were analyzed using a BD FACS Canto II flow cytometer (BD
11 Bioscience). The numbers of neutrophils and macrophages were estimated by multiplying the
12 total leukocyte number by the proportion of each fraction.

13

14 **RNA extraction and quantitative real-time RT-PCR**

15 Total RNA was extracted from wound tissues using ISOGEN (Nippon Gene Co. Ltd., Tokyo,
16 Japan), and first-strand cDNA was synthesized using a PrimeScript first-strand cDNA
17 synthesis kit (TaKaRa Bio Inc., Otsu, Japan), in accordance with the manufacturer's
18 instructions. Quantitative real-time polymerase chain reaction (PCR) was performed in a
19 volume of 20 µL using gene-specific primers and FastStart essential DNA green master mix
20 (Roche Applied Science, Branford, CT, USA) in a Step One[™] (Thermo Fisher, Waltham,
21 MA, USA). Primers were as follows: 5'-CCTTGAGGCCCATTC-3' (Forward) and 5'-
22 GCAACCACTACTACCACAAAGCA-3' (Reverse) for Dectin-1; 5'-CTG GAG CAC CAG

1 TGA GCA GAA C-3' (Forward), and 5'-CCA TTT GCC ATT ACC TTG TGG A-3' (Reverse)
2 for Dectin-2; 5'-AAG ACA AGG CAG CGG TGG AA-3' (Forward) and 5'- GCA GGG GAC
3 AGG AAA TAG TT-3' (Reverse) for COL1A1; 5'-GGA CCA GGC AAT GAT GGA AAA
4 CC-3' (Forward) and 5'-ACC AGG GAA ACC CAT GAC ACC-3' (Reverse) for COL3A1; 5'-
5 TAC GCC TGA GTG GCT GTC TTT T-3' (Forward) and 5'-CGT GGA GTT TGT TAT CTT
6 TGC TGT-3' (Reverse) for TGF- β ; 5'-CCC CTG ATG TCC AGC AAG TAG A-3' (Forward)
7 and 5'-AGT CTG CGA TGA GCT TAG GGA AA-3' (Reverse) for MMP-2; 5'-GAT TCA
8 GAA ACG TGG ACT CAA-3' (Forward) and 5'-CAT CAA GGC ACC AGG ATC AGT-3'
9 (Reverse) for MMP-8; and 5'-GCT TCC TCA GAC CGC TT-3' (Forward) and 5'-TCG CTA
10 ATC ACG CTG GG-3' (Reverse) for β -actin (ACTB). The reaction efficiency with each
11 primer set was determined using standard amplifications. Target gene expression levels and
12 that of ACTB as a reference gene were calculated for each sample using the reaction
13 efficiency. The results were analyzed using a relative quantification procedure and are
14 presented as expression levels relative to ACTB expression.

15

16 **Measurement of cytokine concentrations**

17 The wound tissues were homogenated with saline solution, and the concentrations of cytokine
18 and chemokine in the supernatants were measured using appropriate enzyme-linked
19 immunosorbent assay (ELISA) kits (BioLegend for TNF- α and IL-17A; R&D Systems for
20 CXCL1, CXCL2, and CCL2). The results were expressed as the values per wound.

21

22 **Western blot analysis**

1 Frozen skin wound tissues were weighed and homogenized in RIPA buffer (Wako Pure
2 Chemical Industries, Osaka, Japan) supplemented with Protease Inhibitor Cocktail (Sigma-
3 Aldrich) on ice. After centrifugation at 20,000 $\times g$ for 20 min at 4°C, the protein concentration
4 was determined using the bicinchoninic acid method (Pierce Biotechnology, Rockford, IL,
5 USA). An equal amount of protein per sample was separated by SDS-PAGE using gradient
6 gels (4–20% Tris-Glycine gels, Bio-Rad Laboratories) and transferred to polyvinylidene
7 difluoride membranes (ATTO Corporation, Tokyo, Japan) using a semidry transblot system
8 (ATTO Corporation). Non-specific binding on the blots was blocked with 0.5% (w/v) skim
9 milk and 0.1% (v/v) Tween 20 in TBS for 2 hours at RT, followed by incubation for 1 hour at
10 RT with primary antibodies (rabbit polyclonal anti-Cit H3, 1:1000, Abcam; rabbit polyclonal
11 anti-H3, 1:2000, cell signaling; mouse anti-GAPDH, 1:2000, MBL, Nagoya, Japan) overnight
12 at 4°C. Blots were incubated with appropriate HRP-conjugated secondary antibodies (goat
13 anti-rabbit IgG, 1:5000, cell signaling; goat anti-mouse IgG, 1:5000, cell signaling) for 1 hour
14 at RT. The blots were developed with enhanced chemiluminescence substrate (Nacalai
15 Tesque, cat. no. 11644). Chemiluminescent signals were detected using ImageQuant LAS
16 4000 analyzer (FujiFilm, Tokyo, Japan). Blots were quantified using ImageJ software.

17

18 **Measurement of neutrophil elastase activity**

19 The wound tissue was homogenized with PBS, and the concentration of elastase activity was
20 measured using the EnzChek Elastase Assay Kit (Thermo Fisher), in accordance with the
21 manufacturer's instructions. The results were expressed as the values per wound. The
22 detection limit was 0.004 U/mL.

1

2 Preparation of skin supernatant using wounded tissues and Dectin-1- and Dectin-2-**3 NFAT–GFP reporter assay**

4 Mice were sacrificed at 24 hours after wound creation. The wounded tissues were excised
5 using a biopsy punch (8 mm in diameter) and the tissue from six wounds was homogenized in
6 2 mL of RPMI 1640 medium using stainless-steel mesh. After homogenization, most dead
7 cells were removed by passing the cells through an 8- μ m cell strainer (BD Falcon).

8 T cell hybridoma 2B4 cells were transfected with the NFAT-GFP construct prepared by
9 fusing three tandem NFAT-binding sites with enhanced GFP cDNA (Ohtsuka et al., 2004).

10 This cell line was transfected with Dectin-1 or Dectin-2 and FcR γ genes, and the same cell
11 line lacking Dectin-1 or Dectin-2 was used as a control. These cells were stimulated with the
12 above-mentioned skin supernatant or 60 μ g/mL dZymosan for Dectin-1 reporter cells, or 3
13 mg/mL α -mannan for Dectin-2 reporter cells as a positive control, for 20 hours. Additionally,
14 10% FCS RPMI 1640 medium was used as a control medium. After the stimulation, these
15 cells were stained with allophycocyanin (APC)-anti-CD3 mAb. GFP expression was analyzed
16 in the CD3⁺ cells but not in the dead 7-aminoactinomycin D (7-AAD)-stained cells by flow
17 cytometry.

18

19 Statistics

20 Data are expressed as the mean \pm standard deviation (SD). Data analysis was performed using
21 Welch's *t*-test to compare two experimental groups, and a one-way ANOVA with post-hoc
22 Dunnett's or Turkey–Kramer's honestly significant difference (HSD) test was used for more

1 than three experimental groups. A p value less than 0.05 was considered to indicate
2 significance.

3

4 **Study approval**


5 All experimental protocols described in the present study were approved by the Ethics
6 Review Committee for Animal Experimentation of Tohoku University and performed in
7 accordance with institutional ethical guidelines.

8


9

10

11




Supplementary Figure S1. Dectin-1 and Dectin-2 expression in the wounded tissues at day 5
 Flow cytometric analysis of Dectin-1 and Dectin-2-expressing cells (neutrophils, macrophages, and fibroblasts) at day 5 after wound creation.




Supplementary Figure S2. Dectin-1 and Dectin-2-NFAT-GFP reporter assay

The NFAT-GFP reporter cells expressing Dectin-1 or Dectin-2 were cultured with supernatants that were collected from the wounded tissues 24 hours after wound creation, and GFP expression was analyzed using flow cytometry. Vehicle, dZymosan, and α -mannan were used as controls. Reporter cells expressing FcR γ alone were used as control (CNT) cells.




Supplementary Figure S3. Involvement of CARD9 in the effects of topical administration of dZymosan or α -mannan

CARD9 is an essential signaling adaptor molecule via CLRs. Wounded WT or CARD9KO mice received dZymosan, α -mannan, or vehicle immediately after wounding. The percent of wound closure was evaluated on day 5 (n=18 wounds/group). Each column represents the mean \pm standard deviation. * p < 0.05, ** p < 0.01




Supplementary Figure S4. Topical administration of Furfurman (another Dectin-2 ligand) leads to delayed wound closure. Furfurman is derived from *Malassezia furfur* cell walls. Wounded WT mice received Furfurman, vehicle, or mannan immediately after wounding. The percent of wound closure was evaluated on day 5 (n=18 wounds/group). Each column represents the mean \pm standard deviation. $*p < 0.05$




Supplementary Figure S5. Effects of dZymosan or α -mannan topical administration on neutrophil accumulation

Wounded WT mice received dZymosan, α -mannan, or vehicle immediately after wounding. The number of neutrophils that were stained with Ly6G antibody was analyzed at 6 hours and on day 5. Arrowheads indicate Ly6G-positive neutrophils. The neutrophil density/mm² was determined by counting the positive cells (n = 6 wounds/group). Scale bar = 20 μ m




Supplementary Figure S6. Effects of topical dZymosan or α -mannan administration on the neutrophil accumulation in Dectin-1KO or Dectin-2KO

(a) Wounded Dectin-1KO or WT mice received dZymosan or vehicle immediately after wounding. The number of neutrophils in the wounded tissue was analyzed at 6 hours after wound creation. Six wounds were created in one mouse, which were combined into one sample, and five mice were analyzed in each group. (b) Wounded Dectin-2KO or WT mice received α -mannan (Mannan) or vehicle immediately after wounding. The number of neutrophils in the wounded tissue was analyzed at day 3 after wound creation. Six wounds were created in one mouse, which were put combined one sample, and five mice were analyzed in each group. Each column represents the mean \pm standard deviation. * $p < 0.05$, ** $p < 0.01$



Supplementary Figure S7. Effects of topical dZymosan or α -mannan administration on leukocyte and macrophage accumulation. Wounded WT mice received dZymosan, α -mannan, or vehicle immediately after wounding. (a) The numbers of leukocytes and macrophages in the wounded tissue were analyzed by flow cytometry at 6, 12, and 24 hours and on days 3, 5, and 7 after wound creation. Six wounds were created in one mouse, which were combined into one sample, and five mice were analyzed in each group. (b) MCP-1 levels in the wounded tissue homogenates were measured at 6 hours and on day 3. Six wounds were created in one mouse, which were combined into one sample, and five mice were analyzed in each group. The dotted line indicates the baseline of un-wounded skin. Each column represents the mean \pm standard deviation. * $p < 0.05$, ** $p < 0.01$



Supplementary Figure S8. Distinct roles for Dectin-1 and Dectin-2 in skin wound healing and neutrophilic inflammatory responses

Dectin-1 and Dectin-2 contribute to inflammatory responses that are triggered by β -glucan and α -mannan, which are both derived from the fungal cell wall. Additionally, vimentin and β -glucuronidase from damaged tissues may also be involved in these responses. The main findings in the current study are as follows: 1) Dectin-1 and Dectin-2 were expressed in neutrophils, macrophages, and fibroblasts at the wound sites; 2) Dectin-1 contributed to the acceleration of wound healing by inducing early phase neutrophil accumulation via KC and MIP-2 production; and 3) Dectin-2 was involved in prolonged neutrophilic responses and NET formation, leading to delayed wound healing accompanied by TNF- α and IL-17A induction.

Thus, for skin wound healing, Dectin-1 and Dectin-2 showed distinct roles through their different effects on the neutrophilic response.




Figure 5. R1

175x192mm (300 x 300 DPI)

1 SUPPLEMENTARY MATERIALS AND METHODS

2 Mice

3 Dectin-1 KO mice were generated by homologous recombination of the *Clec7a* gene as
4 described previously (Saijo and Iwakura, 2011) and backcrossed to C57BL/6 mice for eight
5 generations. Dectin-2 gene-disrupted (knockout [KO]) mice were generated by homologous
6 recombination of the *Clec4n* gene as described previously (Saijo et al., 2010) and backcrossed
7 to C57BL/6 mice for seven generations or for more than eight generations. CARD9 KO mice
8 were generated and established as described previously (Hara et al., 2007) and backcrossed to
9 C57BL/6 mice for more than eight generations. Wild-type (WT) littermate mice of Dectin-
10 2KO mice were used as controls for seven generations. Except for experiments with Dectin-
11 2KO mice that were established over seven generations, C57BL/6 mice purchased from
12 CLEA Japan (Tokyo, Japan) were used as WT control. Male mice at 7 to 10 weeks of age
13 were used in the experiments. Food and water were available *ad libitum*. All mice were kept
14 under specific pathogen-free conditions in the Institute for Animal Experimentation, Tohoku
15 University Graduate School of Medicine (Sendai, Japan).

16

17 Wound creation and tissue collection

18 All wound creation was performed under anesthesia that was induced by an intraperitoneal
19 injection of 40 mg/kg sodium pentobarbital (Somnopentyl, Kyoritsu Seiyaku Corporation,
20 Tokyo, Japan), and sustained by inhalation anesthesia of isoflurane (Isoflurane, Mairan
21 Pharma, Osaka, Japan). The dorsal hair was shaved to fully expose the skin, which was then
22 rinsed with 70% ethanol. Six full-thickness wounds extending to the panniculus carnosus

1 were created on each mouse using a 3-mm diameter biopsy punch (Biopsy Punch, Kai
2 Industries Co., Ltd., Gifu, Japan) under sterile conditions. The wounds were covered with a
3 polyurethane film (Tegaderm Transparent Dressing, 3M Health Care, St. Paul, MN, USA)
4 and an elastic adhesive bandage (Hilate, Iwatsuki, Tokyo, Japan) as an occlusive dressing.
5 The day on which the wounds were made was day 0. At various time points, mice were
6 sacrificed and wound tissue was collected by excising the tissue using an 8-mm diameter
7 biopsy punch.

8

9 **Treatment with dZymosan (zymosan depleted) or α -mannan**

10 dZymosan (zymosan depleted), which was prepared from *Saccharomyces cerevisiae* cell
11 walls treated with hot alkali to remove all their TLR-stimulating properties, was purchased
12 from Invivogen (San Diego, CA, USA) and diluted with phosphate buffered saline (PBS) at
13 0.5 mg/mL. Mannan from *Saccharomyces cerevisiae* (α -mannan) was purchased from Sigma-
14 Aldrich (St. Louis, MO, USA) and diluted with phosphate buffered saline (PBS) at 10
15 mg/mL. Wounds were created in accordance with the method described above, and
16 immediately after wounding, a 3- μ L suspension of dZymosan (2.5 μ g), α -mannan (30 μ g), or
17 PBS as a vehicle control was applied to the base of the wounds in WT, Dectin-1KO, or
18 Dectin-2KO mice.

19

20 **Administration of deoxyribonuclease (DNase) I**

21 DNase I, a deoxyribonuclease for single-stranded DNA and double-stranded DNA, was
22 purchased from FUJIFILM Wako Pure Chemical Co. (Osaka, Japan) and dissolved in normal

1 saline at a concentration of 250 U/mL. To inhibit single- and double-stranded DNA, WT mice
2 and WT mice treated with α -mannan were injected intraperitoneally with a 200 μ L suspension
3 of DNase I (50 U) each day from 1 day before wounding to 1 day before tissue collection. As
4 a control group for the relevant experiments, mice were injected with normal saline at the
5 same time points.

6

7 **Neutrophil depletion with anti-Gr-1 antibody**

8 Anti-Gr-1 monoclonal antibody was purified from hybridoma culture supernatants (clones
9 RB6-8C5) using a protein G column kit (Kirkegaard & Perry Laboratories, Gaithersburg,
10 MD, USA). This monoclonal antibody (Gr-1) completely depletes mouse neutrophils (Miura
11 et al., 2019). To neutralize the biological activity of neutrophils, mice were injected
12 intraperitoneally with 400 μ g of mAb at 24 hours after wounding. Rat IgG (ICN
13 Pharmaceuticals, Aurora, OH, USA) was used as a control antibody.

14

15 **Measurement of wound areas**

16 Wound areas were measured on digital images that were obtained with a digital camera (CX4;
17 Ricoh, Tokyo, Japan). After the wounds were created, photographs were taken of each wound
18 before dressing. At various time points, the polyurethane films were removed from the mice
19 and the wounds were photographed. Each wounded area was quantified by tracing its margin
20 and calculating the pixel area using AxioVision imaging software, release 4.6 (Carl Zeiss
21 Micro Imaging Japan, Tokyo, Japan). The percentage of wound closure was calculated using
22 the following formula: % wound closure = $(1 - \text{wound area at the indicated time point} /$

1 wound area 1 on day 0) \times 100.

2

3 **Analysis of hydroxyproline content**

4 Wounds were removed using an 8-mm diameter biopsy punch after mice were sacrificed, and
5 total wound hydroxyproline content was assayed. Briefly, all wound tissue was homogenized
6 and then hydrolyzed in 6N HCl for 21 hours at 120°C. The hydrolysate was neutralized with
7 NaOH. In the next step, 2-mL aliquots were analyzed calorimetrically for hydroxyproline
8 content adding 1 mL of 0.05 mol/L chloramine T (Nacalai Tesque, Kyoto, Japan), 1 mL of
9 3.15 mol/L perchloric acid (Nacalai Tesque), and 1 mL of 20% dimethylaminobenzaldehyde
10 (Nacalai Tesque). The optical densities of the samples were determined using a
11 spectrophotometer at 557 nm.

12

13 **Histology and immunohistochemistry**

14 The removed wound tissues were fixed with 4% paraformaldehyde-phosphate buffer solution
15 and embedded in paraffin. Sections were taken from the central portion of the wound and
16 stained with hematoxylin-eosin (HE) in accordance with the standard method. The extent of
17 re-epithelialization in each wound was measured in these HE-stained sections by measuring
18 the distance from the normal wound margin to the edge of the epithelium. The re-
19 epithelialization index was determined based on the percentage of new epithelium that was
20 present in the total wound.

21 For immunohistochemistry, after blocking with endogenous peroxidase using methanol/
22 hydrogen peroxide, the sections were incubated with 10% normal rabbit serum for 20 min to

1 block non-specific binding and then stained with anti-Dectin-1 Ab (dilution 1:25;
2 BioLegend, San Diego, CA, USA), anti-Dectin-2 Ab (dilution 1:100; Bio-Rad Laboratories,
3 Hercules, CA, USA), anti-Vimentin Ab (dilution 1:100; Abcam plc, Cambridge, UK), anti-
4 β -glucuronidase (dilution 1:100; Proteintech, Rosemont, IL, USA), anti-proliferating cell
5 nuclear antigen (PCNA) Ab (dilution 1:100; Agilent Technologies, Santa Clara, CA, USA),
6 anti- α -smooth muscle actin (α -SMA) Ab (dilution 1:300; Vector Laboratories, Inc.,
7 Burlingame, CA, USA), and anti-CD31 (PECAM-1) Ab (0.25 μ g/mL; Santa Cruz
8 Biotechnology, Santa Cruz, CA, USA). The sections were incubated with peroxidase-
9 conjugated secondary Ab (4 μ g/mL; Histofine Simple Stain MAX-PO, Nichirei Bioscience,
10 Tokyo, Japan).

11 Epithelial cell differentiation, vascular density in the granulation tissue, and
12 myofibroblast differentiation were determined by counting the number of PCNA-positive
13 epithelial cells, the number of CD31-positive vessels, and the number of α -SMA-positive
14 cells, respectively. All analyses were performed under blinded conditions.

15 For fluorescent immunostaining, the tissues were embedded in OCT compound (Sakura
16 Finetechnical Co., Tokyo, Japan) and quickly frozen. The sections were taken from the
17 central portion of the wound, blocked with 10% normal goat serum (Nichirei Bioscience,
18 Tokyo, Japan), and incubated with a primary Ab against citrullinated histone H3 (Cit H3)
19 (rabbit) (0.04 μ g/mL; Abcam) and anti-Ly6G (rat) (clone 1A8, 5 μ g/mL; BioLegend) at 4°C
20 overnight, and then with Alexa 488-conjugated secondary Ab (anti-rabbit) (0.02 μ g/mL; Life
21 Technologies, Tokyo, Japan) and Alexa 555-conjugated secondary Ab (anti-rat) (0.02 μ g/mL;
22 Life Technologies) for 30 min at room temperature (RT). After the sections were covered

1 with mountant (VECTASHIELD® Hard Set Mounting Medium; Vector Laboratories, Inc.),
2 images were acquired by fluorescence microscopy (FSX100; Olympus, Tokyo, Japan).

3

4 **Preparation of leukocytes in the wound tissue**

5 Mice were sacrificed at 6, 12, or 24 hours or on days 3, 5, or 7 after wound creation. The
6 wound tissues were excised using a biopsy punch (8 mm in diameter) and teased apart using
7 stainless-steel mesh in RPMI 1640 medium (Nipro, Osaka, Japan) supplemented with 10 mM
8 HEPES, 10% fetal calf serum (FCS) (BioWest, Nuaille, France), 1 mg/mL collagenase, and 1
9 mg/mL hyaluronidase (Sigma-Aldrich). They were incubated for 2 hours at 37°C with
10 vigorous shaking. After incubation, the tissue fragments and most dead cells were removed by
11 passing the cells through a 70-µm cell strainer (BD Falcon, Bedford, MA, USA). They were
12 then washed three times with 1% FCS RPMI 1640 medium and used as skin leukocytes for
13 flow cytometric analysis.

14

15 **Analysis of Dectin-1, 2-positive cells using flow cytometry**

16 The cells obtained from the wound tissues were stained with Pacific blue-anti-CD45
17 monoclonal antibody (mAb) (clone 30-F11, BioLegend), allophycocyanin cyanin 7
18 (APC/Cy7)-anti-Ly6G mAb (clone 1A8, BioLegend), phycoerythrin (PE)-anti-F4/80 mAb
19 (clone BM8, BioLegend), allophycocyanin (APC)-anti-CD140a mAb (clone APA5,
20 BioLegend), APC-anti-Dectin-1 mAb (clone RH1, BioLegend), and fluorescein
21 isothiocyanate (FITC)-anti-Dectin-2 mAb (clone KVa7-6E7, Miltenyi Biotec, Bergisch
22 Gladbach, Germany). Isotype-matched irrelevant IgG was used as the control staining.

1 Macrophages and neutrophils were identified as CD45+F4/80+ cells and CD45+Ly6G+ cells,
2 respectively. Fibroblasts were identified as CD45+CD140a+ cells. The stained cells were
3 analyzed using a BD FACS Canto II flow cytometer (BD Bioscience, San Jose, CA, USA).

4

5 **Analysis of leukocyte fraction using flow cytometry**

6 The cells obtained from wounded tissues were stained with Pacific blue-anti-CD45 mAb
7 (clone 30-F11, BioLegend), APC-anti-CD11b mAb (clone M1/70, BioLegend), APC/Cy7-
8 anti-Ly6G mAb (clone 1A8, BioLegend), and Alexa Fluor[®]488-anti-F4/80 mAb (clone BM8,
9 BioLegend). Isotype-matched irrelevant IgG was used for control staining. Macrophages and
10 neutrophils were identified as CD45+CD11b+F4/80+ cells and CD45+CD11b+Ly6G+ cells,
11 respectively. The stained cells were analyzed using a BD FACS Canto II flow cytometer (BD
12 Bioscience). The numbers of neutrophils and macrophages were estimated by multiplying the
13 total leukocyte number by the proportion of each fraction.

14

15 **RNA extraction and quantitative real-time RT-PCR**

16 Total RNA was extracted from wound tissues using ISOGEN (Nippon Gene Co. Ltd., Tokyo,
17 Japan), and first-strand cDNA was synthesized using a PrimeScript first-strand cDNA
18 synthesis kit (TaKaRa Bio Inc., Otsu, Japan), in accordance with the manufacturer's
19 instructions. Quantitative real-time polymerase chain reaction (PCR) was performed in a
20 volume of 20 μ L using gene-specific primers and FastStart essential DNA green master mix
21 (Roche Applied Science, Branford, CT, USA) in a Step One[™] (Thermo Fisher, Waltham,
22 MA, USA). Primers were as follows: 5'-CCTTGGAGGCCCATTC-3' (Forward) and 5'-

1 GCAACCACTACTACCACAAAGCA-3' (Reverse) for Dectin-1; 5'-CTG GAG CAC CAG
2 TGA GCA GAA C-3' (Forward), and 5'-CCA TTT GCC ATT ACC TTG TGG A-3'
3 (Reverse) for Dectin-2; 5'-AAG ACA AGG CAG CGG TGG AA-3' (Forward) and 5'- GCA
4 GGG GAC AGG AAA TAG TT-3' (Reverse) for COL1A1; 5'-GGA CCA GGC AAT GAT
5 GGA AAA CC-3' (Forward) and 5'-ACC AGG GAA ACC CAT GAC ACC-3' (Reverse) for
6 COL3A1; 5'-TAC GCC TGA GTG GCT GTC TTT T-3' (Forward) and 5'-CGT GGA GTT
7 TGT TAT CTT TGC TGT-3' (Reverse) for TGF- β ; 5'-CCC CTG ATG TCC AGC AAG TAG
8 A-3' (Forward) and 5'-AGT CTG CGA TGA GCT TAG GGA AA-3' (Reverse) for MMP-2;
9 5'-GAT TCA GAA ACG TGG ACT CAA-3' (Forward) and 5'-CAT CAA GGC ACC AGG
10 ATC AGT-3' (Reverse) for MMP-8; and 5'-GCT TCC TCA GAC CGC TT-3' (Forward) and
11 5'-TCG CTA ATC ACG CTG GG-3' (Reverse) for β -actin (ACTB). The reaction efficiency
12 with each primer set was determined using standard amplifications. Target gene expression
13 levels and that of ACTB as a reference gene were calculated for each sample using the
14 reaction efficiency. The results were analyzed using a relative quantification procedure and
15 are presented as expression levels relative to ACTB expression.

16

17 **Measurement of cytokine concentrations**

18 The wound tissues were homogenated with saline solution, and the concentrations of cytokine
19 and chemokine in the supernatants were measured using appropriate enzyme-linked
20 immunosorbent assay (ELISA) kits (BioLegend for TNF- α and IL-17A; R&D Systems for
21 CXCL1, CXCL2, and CCL2). The results were expressed as the values per wound.

22

1 **Western blot analysis**

2 Frozen skin wound tissues were weighed and homogenized in RIPA buffer (Wako Pure
3 Chemical Industries, Osaka, Japan) supplemented with Protease Inhibitor Cocktail (Sigma-
4 Aldrich) on ice. After centrifugation at $20,000 \times g$ for 20 min at 4°C , the protein concentration
5 was determined using the bicinchoninic acid method (Pierce Biotechnology, Rockford, IL,
6 USA). An equal amount of protein per sample was separated by SDS-PAGE using gradient
7 gels (4–20% Tris-Glycine gels, Bio-Rad Laboratories) and transferred to polyvinylidene
8 difluoride membranes (ATTO Corporation, Tokyo, Japan) using a semidry transblot system
9 (ATTO Corporation). Non-specific binding on the blots was blocked with 0.5% (w/v) skim
10 milk and 0.1% (v/v) Tween 20 in TBS for 2 hours at RT, followed by incubation for 1 hour at
11 RT with primary antibodies (rabbit polyclonal anti-Cit H3, 1:1000, Abcam; rabbit polyclonal
12 anti-H3, 1:2000, cell signaling; mouse anti-GAPDH, 1:2000, MBL, Nagoya, Japan) overnight
13 at 4°C . Blots were incubated with appropriate HRP-conjugated secondary antibodies (goat
14 anti-rabbit IgG, 1:5000, cell signaling; goat anti-mouse IgG, 1:5000, cell signaling) for 1 hour
15 at RT. The blots were developed with enhanced chemiluminescence substrate (Nacalai
16 Tesque, cat. no. 11644). Chemiluminescent signals were detected using ImageQuant LAS
17 4000 analyzer (FujiFilm, Tokyo, Japan). Blots were quantified using ImageJ software.

18

19 **Measurement of neutrophil elastase activity**

20 The wound tissue was homogenized with PBS, and the concentration of elastase activity was
21 measured using the EnzChek Elastase Assay Kit (Thermo Fisher), in accordance with the
22 manufacturer's instructions. The results were expressed as the values per wound. The

1 detection limit was 0.004 U/mL.

2

3 **Preparation of skin supernatant using wounded tissues and Dectin-1- and Dectin-2-**

4 **NFAT–GFP reporter assay**

5 Mice were sacrificed at 24 hours after wound creation. The wounded tissues were excised
6 using a biopsy punch (8 mm in diameter) and the tissue from six wounds was homogenized in
7 2 mL of RPMI 1640 medium using stainless-steel mesh. After homogenization, most dead
8 cells were removed by passing the cells through an 8- μ m cell strainer (BD Falcon).

9 T cell hybridoma 2B4 cells were transfected with the NFAT-GFP construct prepared by
10 fusing three tandem NFAT-binding sites with enhanced GFP cDNA (Ohtsuka et al., 2004).
11 This cell line was transfected with Dectin-1 or Dectin-2 and FcR γ genes, and the same cell
12 line lacking Dectin-1 or Dectin-2 was used as a control. These cells were stimulated with the
13 above-mentioned skin supernatant or 60 μ g/mL dZymosan for Dectin-1 reporter cells, or 3
14 mg/mL α -mannan for Dectin-2 reporter cells as a positive control, for 20 hours. Additionally,
15 10% FCS RPMI 1640 medium was used as a control medium. After the stimulation, these
16 cells were stained with allophycocyanin (APC)-anti-CD3 mAb. GFP expression was analyzed
17 in the CD3⁺ cells but not in the dead 7-aminoactinomycin D (7-AAD)-stained cells by flow
18 cytometry.

19

20 **Statistics**

21 Data are expressed as the mean \pm standard deviation (SD). Data analysis was performed using
22 Welch's *t*-test to compare two experimental groups, and a one-way ANOVA with post-hoc

1 Dunnett's or Turkey–Kramer's honestly significant difference (HSD) test was used for more
2 than three experimental groups. A p value less than 0.05 was considered to indicate
3 significance.

4

5 **Study approval**


6 All experimental protocols described in the present study were approved by the Ethics
7 Review Committee for Animal Experimentation of Tohoku University and performed in
8 accordance with institutional ethical guidelines.

9


10

11


12




119x117mm (300 x 300 DPI)




175x160mm (300 x 300 DPI)





174x99mm (300 x 300 DPI)




174x93mm (300 x 300 DPI)




175x75mm (300 x 300 DPI)



90x139mm (300 x 300 DPI)



175x179mm (300 x 300 DPI)



142x183mm (300 x 300 DPI)